Document:

Exhibit 10.119

 

STOCK PURCHASE AGREEMENT

 

BY AND AMONG

 

GENOMAS, INC.,

 

THE SELLERS SET FORTH IN SCHEDULE D
HERETO,

 

MEDYTOX DIAGNOSTICS, INC.,

 

and

 

RENNOVA HEALTH, INC.

 

September 29, 2016

 

 

 

 

 

 

 

 

 

 

 

 

    	 	 	 

     

    

 

 

TABLE OF CONTENTS

 

 

	ARTICLE I	PURCHASE AND SALE	2
	1.1	Purchase and Sale	2
	1.2	Closing Date	3
	ARTICLE II	REPRESENTATIONS AND WARRANTIES OF SELLERS	3
	2.1	Authorization and Enforceability	3
	2.2	Conflicts; Consents of Third Parties	3
	2.3	The Purchased Shares	3
	2.4	Investor Status	4
	2.5	Brokers Fees	5
	2.6	Genomas Preferred Stock	5
	ARTICLE III	REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY	5
	3.1	Organization and Related Matters	5
	3.2	Books and Records	5
	3.3	Capitalization	6
	3.4	Conflicts; Consents of Third Parties	6
	3.5	Financial Statements	6
	3.6	No Undisclosed Liabilities	7
	3.7	Absence of Certain Developments	7
	3.8	Taxes	10
	3.9	Real and Personal Property	11
	3.10	Intellectual Property, Privacy, Systems and Security	13
	3.11	Contracts	17
	3.12	Employee Benefits	18
	3.13	Labor	18
	3.14	Compliance with Laws; Permits	19
	3.15	Environmental Matters	20
	3.16	Insurance	21
	3.17	Receivables; Payables	21
	3.18	Absence of Certain Business Practices	22
	3.19	Business Continuity	22
	3.20	Bank Accounts; Powers of Attorney	22

 

    	 	i	 

     

    

 

 

	3.21	Brokers Fees	22
	3.22	No Misrepresentation	22
	ARTICLE IV	REPRESENTATIONS AND WARRANTIES OF PURCHASER AND RENNOVA	23
	4.1	Organization	23
	4.2	Authorization and Enforceability	23
	4.3	Conflicts; Consent of Third Parties	23
	4.4	Brokers Fees	23
	4.5	No Proceedings	23
	4.6	Investment Purpose	23
	4.7	Preferred Shares	24
	ARTICLE V	COVENANTS	24
	5.1	Commercially Reasonable Efforts; Notices and Consents	24
	5.2	Access to Information; Financial Statements	25
	5.3	Operation of Business	25
	5.4	Further Assurances; Litigation Support	27
	5.5	Names and Logos	27
	5.6	Mail; Payments; Receivables	27
	5.7	Public Announcements; Confidentiality	28
	5.8	Tax Covenants	28
	5.9	Exclusive Dealing	29
	5.10	Non-Competition; Non-Solicitation	30
	5.11	Resignations	31
	5.12	Tangible Property	31
	5.13	Discharge of Affiliate Obligations	31
	5.14	Preferred Stock	31
	ARTICLE VI	CLOSING CONDITIONS	31
	6.1	Conditions to Obligation of Purchaser and Rennova	31
	6.2	Conditions to Obligation of Sellers	33
	6.3	Corporate Approvals	34
	ARTICLE VII	 INDEMNIFICATION	34
	7.1	Indemnity Obligations of Sellers	34
	7.2	Indemnity Obligations of Purchaser and Rennova	35

 

 

    	 	ii	 

     

    

 

 

	7.3	Indemnification Procedures	35
	7.4	Expiration of Representations and Warranties	36
	7.5	Indemnification Payments to Purchaser Indemnitees; Right of Set-Off	36
	7.6	Treatment of Indemnification Payments	37
	7.7	Right to Indemnification Not Affected by Knowledge or Waiver	37
	ARTICLE VIII	TERMINATION	37
	8.1	Termination of Agreement	37
	ARTICLE IX	MISCELLANEOUS	38
	9.1	Certain Definitions	38
	9.2	Expenses	43
	9.3	Governing Law; Jurisdiction; Venue	43
	9.4	Entire Agreement; Amendments and Waivers	43
	9.5	Section Headings	44
	9.6	Notices	44
	9.7	Severability	44
	9.8	Binding Effect; Assignment; Third-Party Beneficiaries	44
	9.9	Counterparts	45
	9.10	Remedies Cumulative	45
	9.11	Schedules	45
	9.12	Interpretation	45
	9.13	Arm’s Length Negotiations	45
	9.14	Construction	45
	9.15	Specific Performance	46
	9.16	Waiver of Jury Trial	46
	9.17	Time of Essence	46

 

 

 

	Schedule A	Credit & Lender Report
	Schedule B(i)-(iii)	Financial Statements
	Schedule C	Accounts Receivable and Notes Receivable
	Schedule D	Sellers and Shares
	Schedule E	Shares
	Schedule F	Cash Requirement Schedule
	Schedule G	Genomas Intellectual Property
	Schedule H	Leased Property
	Schedule I	NIH Funding
	Schedule J	Insurance Coverage
	Schedule K	Brokerage Agreement
	Schedule L	Licenses & Permits
	Schedule M	Genomics Contract
	Schedule N	Bank Accounts; Powers of Attorney
	Schedule O	Form of Certificate of Designation

 

 

    	 	iii	 

     

    

 

Stock Purchase Agreement

 

THIS STOCK PURCHASE
AGREEMENT (this “Agreement”), dated as of September 29, 2016, is by and among GENOMAS, INC.,
a Delaware corporation (the “Company”), the stockholder sellers set forth in Schedule D hereto (each,
a “Seller” and, collectively, the “Sellers”), MEDYTOX DIAGNOSTICS, INC., a Florida
corporation (“Purchaser”), a wholly-owned subsidiary of RENNOVA HEALTH, INC., a Delaware corporation
(“Rennova”), and Rennova. The Company, Sellers, Purchaser and Rennova are sometimes referred to herein collectively
as the “Parties” and each individually as a “Party.”

 

WHEREAS, the
Purchaser is a wholly-owned subsidiary of Rennova;

 

WHEREAS, Rennova
owns and operates five diagnostics laboratories across the United States that provide clinical testing services specializing in
toxicology testing for pain management clinics, drug and alcohol rehabilitation facilities and neurotransmitter testing. It also
offers its customers a complete, turnkey software product including: a proprietary laboratory ordering and reporting application,
an advanced laboratory information management system, electronic health records, and an industry-leading platform for interpreting
and reporting complex test results to physicians;

 

WHEREAS, the
Company is a biomedical company delivering Personalized Medicine to modern clinical practice. The Company develops revolutionary
PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease and diabetes.
PhyzioType systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and
most effective drug to achieve treatment goals and enhance patient compliance. PhyzioType Systems are composed of an ensemble of
inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted
comparisons of side effect risk and efficacy among drugs for the individual patient;

 

WHEREAS, the
parties agree that the Purchaser will acquire 100% of the Company and the Company will become a wholly-owned subsidiary of the
Purchaser;

 

WHEREAS, Sellers
own the shares of common stock of the Company, par value $0.001 per share (the "Common Stock"), the shares of
Series A Preferred Stock, par value $0.001 per share (the "Series A Preferred"), the shares of Series B Preferred
Stock, par value $0.001 per share (the "Series B Preferred"), and the shares of Series C Preferred Stock, par
value $0.001 per share (the "Series C Preferred"), set forth in Schedule D (such shares of Common Stock, Series
A Preferred, Series B Preferred and Series C Preferred, collectively, the "Purchased Shares");

 

WHEREAS, the
Purchased Shares constitute all of the issued and outstanding equity securities of the Company not owned by Rennova; and

 

WHEREAS, the
Parties desire for Purchaser to purchase from each of Sellers, and for each of Sellers to sell to Purchaser, the respective number
of Purchased Shares set forth opposite such Seller’s name in Schedule D hereto under the heading “Number of
Shares Owned,” subject to the terms and conditions set forth herein.

 

 

 

    	 	1	 

     

    

 

NOW, THEREFORE,
in consideration of the mutual covenants, representations and warranties made herein and other good and valuable consideration,
the receipt and sufficiency of which hereby are acknowledged, the Parties agree as follows:

 

ARTICLE
I

PURCHASE AND SALE

 

Section 1.1.Purchase
and Sale.

 

(a)       On
and subject to the terms and conditions of this Agreement, at the closing of the transactions contemplated hereby (the “Closing”),
Sellers shall sell to Purchaser, free and clear of all Liens (other than any restrictions under the Securities Act and Blue Sky
Laws), and Purchaser shall purchase from Sellers, all of the Purchased Shares. In furtherance thereof, at the Closing each Seller
shall deliver to Purchaser, free and clear of all Liens (other than any restrictions under the Securities Act and Blue Sky Laws),
any stock certificates representing the Purchased Shares, each duly endorsed in blank or with duly executed stock powers attached,
with all required stock transfer tax stamps affixed thereto.

 

(b)       The
aggregate consideration for the Purchased Shares acquired by Purchaser hereunder (collectively, the “Transaction Consideration”)
shall consist of $1,750,000 to be paid in the form of shares of Series F Convertible Preferred Stock, par value $0.01 per share
(the “Series F Preferred”), by Rennova and to be issued to the Sellers, and as per Schedule E, as the total
consideration and such shares of Series F Preferred shall have terms substantially similar to those contained on Schedule O.

 

(c)       Prior
to a formal closing of the acquisition as proposed herein the Parties agree that it is beneficial to immediately proceed with a
business relationship whereby upon signing this Agreement:

 

(i)       Rennova
will use its sales and marketing capabilities to generate diagnostics testing and reporting for the Company. Orders for this business
will be generated either directly to the Company or from Rennova owned laboratories to the Company at an agreed upon and contracted
price;

 

(ii)       Rennova’s
billing subsidiary will immediately assume responsibility on a contracted basis to generate and manage all billing needs for the
Company; and

 

(iii)       Prior
to the date hereof, Rennova has advanced a total of $326,657.83 in keeping with the attached Schedule F, which cash will
be treated as a pre-payment for diagnostics and reporting services that Rennova owned laboratories may request from the Company.
From the date hereof through the Closing, upon request by the Company Rennova may advance up to additional $100,000.00 for the
same purposes as the funds that have been advanced prior to the date hereof. To the extent such cash advanced (either prior to
or after the date hereof) to the Company is in excess of any payments for any actual diagnostics and reporting services, it shall
be considered a loan by Rennova to the Company (the "Loan").

 

 

 

    	 	2	 

     

    

 

Section 1.2.Closing
Date. The Closing shall take at 10:00 a.m. on the third Business Day following the satisfaction or waiver of the conditions
set forth in Section 6.1 and Section 6.2 of this Agreement (other than those conditions that by their terms cannot be satisfied
until the Closing), or at such other place and time as the Parties shall mutually agree (the date of the Closing, the “Closing
Date”).

 

ARTICLE
II

REPRESENTATIONS AND WARRANTIES OF SELLERS

 

The Sellers represent
and warrant to Purchaser and Rennova, only with regard to themselves and not any other Seller, that the following statements are
correct and complete as of the date hereof and as of the Closing Date.

 

Section 2.1.Authorization
and Enforceability. Each Seller that is not an individual is a limited liability company duly engaged and in good standing
under the laws of its jurisdiction of organization and has all requisite power and authority to own, lease and operate its properties
and to carry on its business. Each Seller has all requisite power and authority, and the requisite legal capacity, to execute and
deliver this Agreement and each other Transaction Document to which he or it is a party, and to consummate the transactions contemplated
hereby and thereby. The execution, delivery and performance by each Seller of this Agreement and each of the Transaction Documents
to which he or it is a party have been duly authorized by all necessary action on the part of each such Seller. This Agreement
and the other Transaction Documents have been duly and validly executed and delivered by each Seller and constitute legal, valid
and binding obligations of each Seller, enforceable against such Seller in accordance with their respective terms, subject to applicable
bankruptcy, insolvency, reorganization, moratorium and similar Laws affecting creditors’ rights and remedies generally and
subject, as to enforceability, to general principles of equity (regardless of whether enforcement is sought in a proceeding at
Law or in equity).

 

Section 2.2.Conflicts;
Consents of Third Parties. The execution and delivery by each Seller of this Agreement and the other Transaction Documents
to which he or it is a party, the consummation of the transactions contemplated hereby or thereby, and compliance by each Seller
with the provisions hereof or thereof do not and will not, with or without the passage of time or the giving of notice: (a) conflict
with, violate, or result in a breach of any provision of the Governing Documents of any Seller; (b) conflict with, violate, result
in the breach or termination of, constitute a default under, result in an acceleration of, constitute a change of control under,
or create in any party the right to accelerate, terminate, modify or cancel, any Contract to which such Seller is a party or by
which such Seller or his or its properties, assets or Purchased Shares are subject; (c) violate any Law or any Order by which such
Seller is bound; or (d) result in the creation of any Liens, subscriptions, options, warrants, calls, proxies, commitments or Contracts
of any kind. No Consent, Order, waiver, declaration or filing with, or notification to any Person, including any Government Body,
is required on the part of any Seller in connection with the execution, delivery and performance of this Agreement or the other
Transaction Documents, or the compliance by any of them with any of the provisions hereof or thereof.

 

Section 2.3.The
Purchased Shares. Each Seller holds of record and owns beneficially all of the Purchased Shares set forth opposite such Seller’s
name in Schedule D attached hereto under the heading “Number of Shares Owned,” free and clear of all Liens,
subscriptions, commitments and restrictions of any kind (other than restrictions under the Securities Act and Blue Sky Laws). The
number of Purchased Shares set forth opposite such Seller’s name in Schedule D hereto under the heading “Number
of Shares Owned” correctly sets forth all of the capital stock of the Company owned of record or beneficially by such Seller.
Such Seller’s Purchased Shares were not issued in violation of (i) any law, rule or regulation, (ii) any Contract to which
such Seller is or was a party or beneficiary or by which such Seller or his or its properties or assets is or was subject, or (iii)
any preemptive or similar rights of any Person. This Agreement, together with the other documents executed and delivered at Closing
by such Seller, will be effective to transfer valid title to such Seller’s Purchased Shares to Purchaser, free and clear
of all Liens and Contracts of any kind.

 

 

 

    	 	3	 

     

    

 

Section 2.4.Investor
Status. Each Seller (a) understands and acknowledges that the Series F Preferred has not been registered under the Securities
Act, or under applicable state securities Laws (“Blue Sky Laws”), in reliance upon exemptions contained in the
Securities Act and Blue Sky Laws and any applicable regulations promulgated thereunder or interpretations thereof, and cannot be
offered for sale, sold or otherwise transferred unless, among other things, such securities subsequently are so registered or qualify
for exemption from registration under the Securities Act and Blue Sky Laws; (b) represents, understands and acknowledges that the
Series F Preferred is being acquired under this Agreement in good faith solely for his or its own account, for investment and not
with a view toward resale or other distribution in violation of the Securities Act or Blue Sky Laws, and that such securities will
not be offered for sale, sold or otherwise transferred without either registration or exemption from registration under the Securities
Act and Blue Sky Laws; (c) has such knowledge and experience in financial and business matters that such Party is capable of evaluating
the merits and risks of the investment in the Series F Preferred, and such Party understands that he or it may have to hold the
Series F Preferred for an indefinite period of time and he or it is able to bear any economic risks associated with such investment
(including the inherent risk of losing all or part of the investment in such Series F Preferred); (d) is personally and directly
familiar with the business that is intended to be conducted by Rennova, including financial matters related to such business, has
been given the opportunity to ask questions of, and receive answers from, the directors and executive officers of Rennova concerning
the business and financial affairs of Rennova , and the terms and conditions of such Party’s acquisition of the Series F
Preferred, and has had further opportunity to obtain any additional information desired (including information necessary to verify
the accuracy of the foregoing); (e) has, at his or its own expense, undertaken an independent analysis of the merits and risks
of the Series F Preferred, including tax and legal consequences of his or its ownership of the Series F Preferred; (f) has been
given an opportunity to review all of Rennova’s filings with the Securities and Exchange Commission; (g) has fully satisfied
himself or itself as to any questions he or it may have concerning Rennova, its assets, its liabilities and the Series F Preferred;
(h) acknowledges that no one associated, directly or indirectly, with Rennova or its affiliates has made any representations or
guaranties to him or it as to the future value or worth of any equity position in Rennova including the Series F Preferred, or,
other than as provided in the Transaction Documents, made any representation regarding Rennova or its business; (i) is an Accredited
Investor, as defined under the Securities Act, and (j) is a resident of the State specified in Schedule D.

 

 

 

    	 	4	 

     

    

 

Section 2.5.Brokers
Fees. Except for Technology Park.Com, no Seller has any Liability to pay any fees or commissions to any investment banker,
broker, finder, agent or any other similar Person with respect to the transactions contemplated by this Agreement. The arrangements
with Technology Park.Com have been disclosed to the Purchaser in writing as set forth in Schedule A as part of the Creditor
& Lender Report and will be paid by Rennova at Closing.

 

Section 2.6.Genomas
Preferred Stock. (i) The holders (each a "Holder") of all of the issued and outstanding Series A Preferred, Series
B Preferred and Series C Preferred agree that this Agreement and the transactions contemplated hereby shall not constitute a liquidation
as defined in Section 2.3 of the Third Amended and Restated Certificate of Incorporation of the Company (the "Certificate
of Incorporation"), (ii) no Holder has voted to or given any request to the Company to, redeem any shares of Series A Preferred,
Series B Preferred or Series C Preferred, (iii) each Holder consents to this Agreement and the transactions contemplated hereby,
and (iv) each Holder consents to and waives any tag along rights relating to the purchase by Rennova of shares of Series A Preferred
and Series B Preferred.

 

ARTICLE
III

REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY

 

The Company and Sellers,
to their best Knowledge and belief, jointly and severally represent and warrant to Purchaser and Rennova that the following statements
are correct and complete as of the date hereof and as of the Closing Date.

 

Section 3.1.Organization
and Related Matters. The Company is a corporation duly organized and in good standing under the Laws of the State of Delaware
and it has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business. The
Company is duly qualified or authorized to do business as a foreign corporation and is in good standing under the Laws of each
jurisdiction in which it owns or leases real property and each other jurisdiction in which the conduct of its business or the ownership
of its properties requires such qualification or authorization. The execution, delivery and performance by the Company of this
Agreement and each of the Transaction Documents to which it is a party have been duly authorized by all necessary action on the
part of the Company. This Agreement and the other Transaction Documents have been duly and validly executed and delivered by the
Company and constitute legal, valid and binding obligations of the Company, enforceable against the Company in accordance with
their respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors'
rights and remedies generally and subject, as to enforceability, to general principles of equity regardless of whether enforcement
is sought in a proceeding at law or in equity. The Company does not have any Subsidiaries.

 

Section 3.2.Books
and Records. The Books and Records, all of which have been provided to Purchaser, are complete and correct and represent actual,
bona fide transactions and have been maintained in accordance with sound business practices. The minute books of the Company, all
of which have been provided to Purchaser, contain accurate and complete records of all meetings held of, and corporate action taken
by, the shareholders, the board of directors and committees of the board of directors of the Company, and no meeting of any such
shareholders, board of directors or committee has been held for which minutes have not been prepared or are not contained in such
minute books.

 

 

 

    	 	5	 

     

    

 

Section 3.3.Capitalization.
Schedule D sets forth the following: (i) the total number of authorized shares of each class of capital stock of the Company,
(ii) the total number of issued and outstanding shares of each class of capital stock of the Company, (iii) the names of the holders
of the issued and outstanding shares of each class of capital stock of the Company, and (iv) the number of shares of each class
of capital stock held by each such holder. No shares of capital stock are held in treasury. All of the shares of capital stock
have been duly and validly authorized and issued, are fully paid and nonassessable, and all such shares are held of record and
owned beneficially as set forth in Schedule D. No shares of capital stock have been issued in violation of any preemptive
rights or any applicable securities Laws. Other than as set forth in Schedule D, the Company has no outstanding or authorized options,
warrants, rights, subscription rights, conversion rights, exchange rights, preemptive rights or other contracts or commitments
that could require the Company to issue, sell, or otherwise cause to become outstanding any of its capital stock or other equity
security, or securities convertible or exchangeable for, or any options, warrants, or rights to purchase, any of such capital stock
or other equity security. There are no outstanding obligations of the Company to repurchase, redeem or otherwise acquire any of
its capital stock or other equity security. There are no outstanding or authorized stock appreciation, phantom equity, profit participation
or similar rights with respect to the Company. There are no dividends which have accrued or been declared but are unpaid on the
capital stock of the Company. There are no voting agreements, voting trusts, proxies, registration rights agreements, stockholder
agreements or other Contracts with respect to any of the shares of capital stock of the Company.

 

Section 3.4.Conflicts;
Consents of Third Parties. The execution and delivery of this Agreement and the other Transaction Documents to which the Company
is a party, the consummation of the transactions contemplated hereby or thereby, and compliance by the Company with the provisions
hereof or thereof do not and will not, with or without the passage of time or the giving of notice: (a) conflict with, or result
in the breach of, any provision of the Governing Documents of the Company; (b) conflict with, violate, result in the breach or
termination of, constitute a default under, result in an acceleration of, constitute a change of control under, or create in any
party the right to accelerate, terminate, modify or cancel, any Contract to which the Company is a party or by which the Company
or its properties or assets are bound, or require a Consent from any Person in order to avoid any such conflict, violation, breach,
termination, default or acceleration; (c) violate any Law or any Order by which the Company is bound; or (d) result in the creation
of any Lien upon the properties or assets of the Company. No Consent, Order, waiver, declaration or filing with, or notification
to any Person, including any Governmental Body, is required on the part of the Company in connection with the execution, delivery
and performance of this Agreement or the other Transaction Documents, or the compliance by any of them with any of the provisions
hereof or thereof.

 

Section 3.5.Financial
Statements.

 

(a)       Included
in Schedule B(i)-(iii) are complete copies of the unaudited balance sheets of the Company as at December 31, 2015 and August 31,
2016 (the "Balance Sheet Date"), and the related unaudited income statement and statement of cash flows of the Company
for the eight months then ended (all of such statements, including the related notes and schedules thereto, the “Financial
Statements”). The Financial Statements have been prepared from the Books and Records in accordance with GAAP applied
on a consistent basis throughout the period indicated, except, in the case of the unaudited financial statements, for the failure
to include the footnotes required by GAAP and subject to normal and non-recurring year-end audit adjustments (which will not be
material in the aggregate). The Financial Statements fairly present in all material respects the financial position and results
of operations, shareholders’ equity and cash flows of the Company as of the dates and for the period reflected thereon. The
Company maintains a standard system of accounting established and administered in accordance with GAAP.

 

 

 

    	 	6	 

     

    

 

(b)       The
Company (i) makes and keeps accurate Books and Records in a consistent manner and (ii) established and maintains a system of “internal
controls over financial reporting” (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934, as amended) sufficient
to provide reasonable assurance (i) regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP, (ii) that receipts and expenditures of the Company are being made only in accordance
with the authorization of the Company’s management and directors, and (iii) regarding prevention or timely detection of the
unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Company’s
financial statements. There has not been (1) any significant deficiency in the design or operation of internal controls which could
affect the ability of the Company to record, process, and summarize its financial data or any material weaknesses in internal controls
of the Company, or (2) any fraud that involves management or other employees who have a significant role in the internal controls
of the Company. Since the Balance Sheet Date, there have been no changes in internal controls or in other factors that could materially
affect internal controls by the Company, including any corrective actions with regard to significant deficiencies and material
weaknesses.

 

Section 3.6.No
Undisclosed Liabilities. The Company has no undisclosed Liabilities (and there is no basis for any present or future Legal
Proceeding against the Company giving rise to any Liability) except (a) to the extent specifically reflected and accrued for or
specifically reserved against in the Balance Sheet; (b) for current Liabilities incurred subsequent to the Balance Sheet Date in
the ordinary course of business consistent with past custom and practice (none of which results from, arises out of, relates to,
is in the nature of, or was caused by any breach of contract, breach of warranty, tort, infringement, or violation of Law) and
(c) those disclosed in Schedule A and Schedule F.

 

Section 3.7.Absence
of Certain Developments. Since the Balance Sheet Date, the Company has not conducted its business other than in the ordinary
course consistent with past practice and:

 

(a)       there
has not been any Company Material Adverse Change nor has there occurred any event which is reasonably likely to result in a Company
Material Adverse Change;

 

(b)       the
Company has not made any declaration or payment of any dividends or distributions on or in respect of any capital stock or other
security of the Company, or redemption, purchase or acquisition of any capital stock or other security of the Company, or made
any other payment to or on behalf of any Seller or any Affiliate thereof;

 

 

 

    	 	7	 

     

    

 

(c)       there
has not been any split, combination or reclassification of any shares of capital stock or other security of the Company;

 

(d)       there
has not been any damage, destruction or loss, whether or not covered by insurance, with respect to the property and assets of the
Company having a replacement cost of more than $5,000 for any single loss or $10,000 in the aggregate for any related losses;

 

(e)       the
Company has not made any change in the rate of compensation, commission, bonus or other direct or indirect remuneration payable,
or paid or agreed or orally promised to pay, conditionally or otherwise, any bonus, incentive, retention or other compensation,
retirement, welfare, fringe or severance benefit or vacation pay, to or in respect of any director, officer, employee, distributor
or agent of the Company, other than increases in the ordinary course of business consistent with past practice in the base wages
or salaries of employees of the Company other than officers or senior managers;

 

(f)       the
Company has not entered into or amended any employment, deferred compensation, severance or similar agreement;

 

(g)       the
Company has not entered into any collective bargaining agreement or relationship with any labor organization;

 

(h)       there
has not been any material change by the Company in accounting or Tax reporting principles, methods or policies, any settlement
of any Tax controversy, any amendment of any Tax Return, or any material Tax election made by or with respect to the Company;

 

(i)       except
for the transactions contemplated by this Agreement, the Company has not entered into or amended any other transaction or Contract
other than in the ordinary course of business consistent with past practice;

 

(j)       the
Company has not hired employees or engaged independent contractors other than in the ordinary course of business consistent with,
and at a level consistent with, past practice;

 

(k)       the
Company has not breached any Contract;

 

(l)       the
Company has not made any loans, advances or capital contributions to, or investments in, any Person that are undisclosed or not
listed in Schedules A and F;

 

(m)       the
Company has not mortgaged, pledged or subjected to any Lien any of its assets, or acquired any assets or sold, assigned, transferred,
conveyed, leased or otherwise disposed of any assets of the Company except for assets acquired or sold, assigned, transferred,
conveyed, leased or otherwise disposed of in the ordinary course of business consistent with past practice;

 

 

 

    	 	8	 

     

    

 

(n)       the
Company has not canceled or compromised any debt or claim or amended, canceled, terminated, relinquished, waived or released any
Contract or right except in the ordinary course of business consistent with past practice and which, in the aggregate, are not
material to the Company;

 

(o)       the
Company has not entered into or amended any Contract or transaction with any of its Affiliates or paid any fees, expenses or other
amounts to any Affiliate of the Company;

 

(p)       the
Company has not made or committed to make any capital expenditures or capital additions or improvements (i) in excess of $5,000
individually or $10,000 in the aggregate, or (ii) outside the ordinary course of business consistent with past practices;

 

(q)       the
Company has not entered into any prepaid transactions or otherwise accelerated revenue recognition or the sales for periods prior
to the Closing outside of the ordinary course of business consistent with past practices;

 

(r)       the
Company has not materially changed its policies or practices with respect to the payment of accounts payable or other current liabilities
or the collection of accounts receivable (including any acceleration or deferral of the payment or collection thereof);

 

(s)       the
Company has not amended any of its Governing Documents;

 

(t)       the
Company has not adopted any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in
bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against
it under any similar Law or other agreement with respect to the sale of its assets, securities or Business;

 

(u)       the
Company has not issued any equity or debt securities or any security exercisable or exchangeable for or convertible into equity
securities of the Company, or incurred any Indebtedness or other Liabilities (other than in the ordinary course of business consistent
with past practices);

 

(v)       the
Company has not (i) discharged, repaid, amended, modified, made payment on, canceled or compromised any Indebtedness, or discharged
or satisfied any Lien, or (ii) engaged in any transaction or provided any consideration relating to the release, modification or
diminution of any guarantee, bond, surety or other obligation of any Seller or any Affiliate thereof;

 

(w)       the
Company has not entered into any compromise or settlement of any Legal Proceeding or investigation by any Governmental Body;

 

(x)       the
Company has not transferred, assigned or granted any license or sublicense of any material rights under or with respect to any
Intellectual Property;

 

(y)       the
Company has not failed (i) to file any material reports or take steps necessary to comply with applicable Laws and (ii) to maintain
in good standing all Permits; and

 

 

 

    	 	9	 

     

    

 

(z)       the
Company has not entered into any agreements or commitments to do or perform in the future any actions referred to in this section.

 

Section 3.8.Taxes.

 

(a)       The
Company has timely filed with the appropriate taxing authorities all Tax Returns that it has been required to file. All such Tax
Returns are true, correct and complete in all respects. All Taxes owed by the Company (whether or not shown on any Tax Return)
have been paid. Adequate reserves have been established on the Financial Statements to provide for the payment of any Taxes which
are not yet due and payable with respect to the Company for taxable periods or portions thereof ending on or before the Balance
Sheet Date. The Company is not the beneficiary of any extension of time within which to file any Tax Return. No written claim has
ever been made by an authority with respect to the Company in a jurisdiction where the Company does not file Tax Returns that it
is or may be subject to taxation by that jurisdiction. There are no Liens on any of the assets of the Company that have arisen
in connection with any failure (or alleged failure) to pay any Tax.

 

(b)       The
Company has withheld and paid to the appropriate taxing authority or other Governmental Body all Taxes required to have been withheld
and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, shareholder, or other third
party.

 

(c)       The
Company has not waived or extended any statute of limitations in respect of Taxes or agreed to any extension of time with respect
to the assessment, payment or collection of any Tax.

 

(d)       The
Company has no obligation to make a payment that is not deductible under Section 280G of the Code or that includes an obligation
to indemnify or “gross up” the recipient of such payment for taxes imposed by Section 4999 of the Code.

 

(e)       None
of the properties or assets of the Company is property which, for Tax purposes, is required to be treated as owned by another Person.
The Company is not an obligor on, and none of its assets have been financed directly or indirectly by, any tax-exempt bonds. No
property or assets of the Company is “tax-exempt use property” within the meaning of Section 168(h) of the Code.

 

(f)       No
deficiency or proposed adjustment which has not been settled or otherwise resolved for any amount of Taxes has been asserted or
assessed by any taxing authority or other Governmental Body against the Company. There has not been, within the past five calendar
years, an audit, examination or written notice of potential examination of any Tax Returns filed by the Company.

 

(g)       There
is no action, suit, examination, investigation, Governmental Body proceeding, or audit or claim for refund in progress, pending,
proposed or, to the Knowledge of the Sellers, threatened against or with respect to the Company regarding Taxes. No Seller and
no director or officer (or employee responsible for Tax matters) of the Company expects any authority to assess any additional
Taxes for any period for which Tax Returns have been filed.

 

 

 

    	 	10	 

     

    

 

(h)       The
Company has not agreed to or been required to make any adjustment pursuant to Section 481(a) of the Code or any corresponding provision
of state, local or foreign Law by reason of any change in accounting method initiated by it or on its behalf; no taxing authority
has proposed any such adjustment or change in accounting method; and the Company has no application pending with any taxing authority
requesting permission for any change in accounting method. The Company will not be required (A) as a result of a change in method
of accounting for a taxable period ending on or prior to the Closing Date, to include any adjustment under Section 481(c) of the
Code in taxable income for any taxable period (or portion thereof) beginning after the Closing or (B) as a result of any “closing
agreement,” as described in Section 7121 of the Code, to include any item of income or exclude any item of deduction from
any taxable period (or portion thereof) beginning after the Closing.

 

(i)       The
Company has not been a member of an affiliated group (as defined in Section 1504 of the Code), filed or been included in a combined,
consolidated or unitary income Tax Return, or is a partner, member, owner or beneficiary of any entity treated as a partnership
or a trust for Tax purposes. The Company has no Liability for Taxes of any Person under Treasury Regulations Section 1.1502-6 or
similar state or local Laws, as a successor or transferee, by contract or otherwise.

 

(j)       The
Company is not a party to or bound by any Tax allocation or Tax sharing agreement and has no contractual obligation to indemnify
any other Person with respect to Taxes.

 

(k)       True,
correct and complete copies of all income and sales Tax Returns filed by or with respect to the Company for taxable periods ending
on or before December 31, 2015 have been delivered to Purchaser.

 

(l)       The
Company has not participated in any reportable transaction as contemplated in Treasury Regulations Section 1.6011-4. The Company
has disclosed on its federal income Tax Returns all positions taken therein that could give rise to a substantial understatement
of federal income Tax within the meaning of Section 6662 of the Code.

 

(m)       The
Company is not subject to Tax, nor does it have a permanent establishment, in any foreign jurisdiction.

 

(n)       The
Company has no pending ruling requests filed by it or on its behalf with any taxing authority or Governmental Body.

 

Section 3.9.Real
and Personal Property.

 

(a)       The
Company does not own nor has owned any real property or interest in real property.

 

 

 

    	 	11	 

     

    

 

(b)       Schedule
H sets forth the address of each parcel of real property and interests in real property leased by the Company as lessee, and
a true and complete list of all leases related to real property currently leased by the Company (individually, a “Real
Property Lease” and the real properties specified in such leases being referred to herein collectively as the “Leased
Properties”). The Company has a valid, binding and enforceable leasehold interest under each of the Real Property Leases,
subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar Laws affecting creditors’ rights and
remedies generally and subject, as to enforceability, to general principles of equity (regardless of whether enforcement is sought
in a proceeding at Law or in equity). The Company has not received any written notice of any default or event that with notice
or lapse of time, or both, would constitute a default under any of the Real Property Leases and the Company and, to the Knowledge
of the Sellers, each other party thereto, is in compliance with all obligations of such party thereunder. The Company has not subleased,
assigned or otherwise granted to any Person the right to use or occupy such Leased Properties or any portion thereof. The Company’s
possession and quiet enjoyment of Leased Property under each Real Property Lease has not been disturbed and there are no disputes
with respect to any Real Property Lease. No security deposit or portion thereof deposited with respect to any Real Property Lease
has been applied in respect of a breach of or default under any such Real Property Lease that has not been redeposited in full.
The Company does not owe, or will owe in the future, any brokerage commissions or finder’s fees with respect to any Real
Property Lease. The Company has not collaterally assigned or granted any other Lien in any Real Property Lease or any interest
therein (other than Permitted Liens). There are no Liens on the estate or interest created by any Real Property Lease (other than
Permitted Liens). Sellers have delivered to Purchaser complete and correct copies of the Real Property Leases, together with all
amendments, modifications or supplements, if any, thereto. The lease identified in Schedule H shall be terminated upon the
Closing of this Agreement.

 

(c)       To
the Knowledge of the Sellers, the Leased Properties are in compliance with all applicable building, zoning, subdivision, health
and safety and other land use Laws, including the Americans with Disabilities Act of 1990, as amended, and all insurance requirements
affecting the Leased Properties (collectively, the “Real Property Laws”), and the current use or occupancy of
the Leased Properties or operation of the Business thereon does not violate any Real Property Laws. The Company has not received
any notice of violation of any Real Property Law. There is no pending or, to the Knowledge of the Sellers, anticipated change in
any Real Property Law that will impact the Leased Properties or any portion thereof in the continued operation of the Business.
There is no pending or, to the Knowledge of the Sellers, threatened zoning application or proceeding or condemnation, eminent domain
or taking proceeding with respect to the Leased Properties.

 

(d)       The
Leased Properties constitute all interests in real property currently used or currently held for use in connection with the Business
or which are necessary for the continued operation of the Business as the Business is currently conducted.

 

(e)       The
Company (and not any Affiliate thereof) has good and marketable title to all its assets, free and clear of any and all Liens, except
for Permitted Liens. Such assets include all assets, rights and interests reasonably required for the continued conduct of the
Business by Purchaser.

 

(f)       All
tangible personal property owned by the Company, and all of the items of tangible personal property used by the Company, are structurally
sound, are in good operating condition and repair, and are adequate for the uses to which they are being put, and none of such
items of tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that
are not material in nature or cost.

 

 

 

    	 	12	 

     

    

 

Section 3.10.Intellectual
Property, Privacy, Systems and Security.

 

(a)       The
Company owns and has independently developed, free and clear from all Liens, or otherwise possesses legally enforceable rights
to use all of the Intellectual Property reasonably necessary to the conduct of the Business as currently conducted. The Intellectual
Property owned by the Company (“Owned Intellectual Property”) and the Intellectual Property licensed to the
Company comprises all of the Intellectual Property that is used in or is reasonably necessary to conduct the Business as currently
conducted (such Intellectual Property being hereinafter collectively referred to as the “Company IP Rights”).

 

(b)       Schedule
G sets forth a true, complete and correct list of all Owned Intellectual Property for which a registration or application has
been filed with a governmental body, including patents, trademarks, service marks, copyrights rights, rights in Internet or World
Wide Web Domain names or URLs with any governmental entity, including Internet domain name registrars; in each case listing, as
applicable, (x) the jurisdiction where the item is located and (y) the application or registration number, and (z) all applications,
registrations, filings and other formal written governmental actions made or taken pursuant to applicable Laws by the Company to
secure, perfect or protect its interest in Company IP Rights, including all patent applications, copyright applications, and applications
for registration of trademarks and service marks. Schedule G sets forth a complete and correct list of all trademarks, service
marks, other trade designations, Software, copyrights, and trade secrets that are Owned Intellectual Property and not otherwise
identified in this Agreement. All required filings and fees related to the Owned Intellectual Property have been timely filed with
and paid to the relevant governmental authority and authorized registrars, and all Owned Intellectual Property is otherwise in
good standing. To the Knowledge of the Sellers, all patents, registered trademarks, service marks, rights in Internet or World
Wide Web domain names or URLs, and copyrights held by the Company are valid, enforceable and subsisting. To the Knowledge of the
Sellers, all items set forth under clause (i) are currently in compliance with all formal legal requirements (including payment
of filing, examination and maintenance fees and proofs of use) and are not subject to any unpaid maintenance fees or taxes or actions.
Schedule G also sets forth a complete and correct list of all written or oral licenses and arrangements (ii) pursuant to
which the use by any Person of Intellectual Property is permitted by the Company or (iii) pursuant to which the use by the Company
of Intellectual Property is permitted by any Person (collectively, the “Intellectual Property Licenses”). The
Intellectual Property Licenses are valid, binding and enforceable between the other parties thereto and are in full force and effect.
There is no material default under any Intellectual Property License by the Company or, to the Knowledge of the Sellers, by any
other party thereto, and no event has occurred that with the lapse of time or the giving of notice or both would constitute a material
default thereunder. The Company and, to the Knowledge of the Sellers, each other party thereto is in compliance with all obligations
under each Intellectual Property License. Other than pursuant to the Intellectual Property Licenses, no Person has any interest
in any Intellectual Property used by the Company.

 

(c)       There
are no royalties, honoraria, fees or other payments payable by the Company to any third Person (other than amounts payable to employees
and independent contractors not contingent on or related to use of their work product) as a result of the ownership, use, possession,
license, sale, marketing, advertising or disposition of any Company IP Rights by the Company to the extent necessary for the conduct
of the Business and none will become payable as a result of the consummation of the transactions contemplated hereby.

 

 

 

    	 	13	 

     

    

 

(d)       To
the Knowledge of the Sellers, no current employee, consultant or independent contractor of the Company: (i) is in violation of
any term or covenant of any employment contract, patent disclosure agreement, invention assignment agreement, non-disclosure agreement,
non-solicitation agreement, non-competition agreement, or any other contract with any other Person by virtue of such employee’s,
consultant’s, or independent contractor’s being employed by, or performing services for, the Company or using trade
secrets or proprietary information of others without permission or (ii) is party to any contract with any prior employer or other
party that prohibits or otherwise restricts such employee, consultant or independent contractor in any material respect from performing
his prior or current duties at the Company; or (iii) has developed any technology, software or other copyrightable, patentable,
or otherwise proprietary work for the Company that is subject to any contract under which such employee, consultant or independent
contractor has assigned or otherwise granted (or agreed to assign or otherwise grant) to any third party any rights (including
Intellectual Property) in or to such technology, software or other copyrightable, patentable or otherwise proprietary work. To
the Knowledge of the Sellers, the employment of any employee of the Company and the use by the Company of the services of any consultant
or independent contractor has not and does not subject the Company to any liability to any third party for improperly soliciting
such employee or consultant, or independent contractor to work for the Company, whether such liability is based on contractual
or other legal obligations to such third party.

 

(e)       The
use of the Company’s IP Rights as presently conducted does not and will not interfere with, infringe upon, misappropriate,
or otherwise come into conflict with, any Intellectual Property rights of third parties.

 

(f)       There
is no claim or demand of any Person pertaining to, or any proceeding which is pending or, to the Knowledge of the Sellers, threatened,
that challenges the rights of the Company in respect of any Owned Intellectual Property, or claims that any default exists under
any Intellectual Property License.

 

(g)       To
the Knowledge of the Sellers, there is no unauthorized use, disclosure, infringement or misappropriation by any third party of
any Owned Intellectual Property or any Intellectual Property Licenses which are exclusively licensed to the Company, including
any employee or former employee of the Company, and the Company has not made any allegations to the contrary. The Company has not
agreed to indemnify any Person against any infringement of any Intellectual Property of any third party with respect to any Proprietary
Software Products, other than indemnification provisions contained in the Company’s purchase orders or other contracts entered
into in the ordinary course of business, all forms of which have been provided or made available to Purchaser.

 

(h)       The
Company has taken all reasonable, necessary and appropriate steps to protect, preserve and maintain the secrecy and confidentiality
of material confidential information of the Company and to preserve and maintain the Company’s interests and proprietary
rights in Company IP Rights (including in each case the source code for all Software in the Proprietary Software Products). To
the Knowledge of the Sellers, there is no misappropriation of any of the Company’s trade secrets by another Person.

 

 

 

    	 	14	 

     

    

 

(i)       All
current and former officers, employees and consultants of the Company who have or have had access to proprietary information and
inventions of the Company has executed and delivered to the Company a binding and enforceable agreement regarding the protection
of such proprietary information; and copies of all such contracts have been provided to Purchaser.

 

(j)       The
Company has secured valid written assignments from all of the Company’s consultants, contractors and employees who conceived
(in whole or in part) of any Owned Intellectual Property, including without limitation, the Proprietary Software Products, to the
extent legally permissible. All work relating to any Intellectual Property done by such employees was within the scope of their
employment and the Company owns all rights to all work performed by such employees.

 

(k)       No
current or former employee, officer, director, consultant or independent contractor of the Company has any right, license, claim
or interest whatsoever in or with respect to any Company IP Rights.

 

(l)       Neither
the Company nor any of its current or former employees, officers, directors, consultants or independent contractors during the
time period of their association with the Company, has made any patentable inventions related to any Proprietary Software Products
or otherwise related to the Company’s Business.

 

(m)       Government
Funding: Except as listed on Schedule I, there shall be no additional government funding, facilities of a university, college,
other educational institution or research center or funding from third parties (other than funds received in consideration for
Company stock) was used in the development of the Proprietary Software Products or any other Owned Intellectual Property or any
Intellectual Property License which are exclusively licensed to the Company. No current or former employee, consultant or independent
contractor of the Company who was involved in, or who contributed to, the creation or development of any Company IP Rights has
performed services for any governmental entity, university, college, or other educational institution or research center during
a period of time during which such employee, consultant or independent contractor was also performing services for the Company.
To the Knowledge of the Sellers, no governmental entity, university, college, or other educational institution or non-profit research
center has any claim or right in or to any Owned Intellectual Property or any Intellectual Property License which are exclusively
licensed to the Company, including any “march in” rights.

 

(n)       All
of the Software and Documentation comprising, incorporated in or bundled with the Customer Offerings or Internal Systems have been
designed, authored, tested and (consistent with current industry standards) debugged by regular employees of the Company within
the scope of their employment or by independent contractors of the Company who have executed valid and binding agreements expressly
assigning all right, title and interest in such copyrightable materials to the Company, waiving their non-assignable rights (including
moral rights) in favor of the Company and its permitted assigns and licensees, and have no residual claim to such materials. The
Company has provided Purchaser with true and complete copies of all such agreements.

 

 

 

    	 	15	 

     

    

 

(o)       The
Customer Offerings and the Internal Systems are free from material defects in design, workmanship and materials and conform in
all material respects to the written Documentation and specifications therefor. To the Knowledge of the Sellers, the Customer Offerings
and the Internal Systems do not contain any disabling device, virus, worm, back door, Trojan horse or other disruptive or malicious
code that may or are intended to impair their intended performance or otherwise permit unauthorized access to, hamper, delete or
damage any computer system, software, network or data. The Company has not received any warranty claims, contractual terminations
or requests for settlement or refund due to the failure of the Customer Offerings to meet their specifications or otherwise to
satisfy end user needs or for harm or damage to any third party.

 

(p)       The
Company and its use of the Intellectual Property have been and are in material compliance with all applicable Laws including, without
limitation HIPAA, and contractual requirements, published privacy policies or statements, and any other policies of the Company
concerning data security requirements, privacy policy notice requirements, data security breach requirements, and requirements
regarding the use, storage, disclosure or transfer of personally identifiable information, which includes Protected Health Information,
as defined in 45 C.F.R. Sec. 160.103 (collectively, “PII”). To the Knowledge of the Sellers, no investigation
relating to the information privacy or data security practices (including collection, transfer, or use) of the Company is being
conducted by any governmental entity. To the Knowledge of the Sellers, there has been no data security breach of any computer systems
or networks, or unauthorized use of any PII that is owned, used, stored, received, or controlled by or on behalf of the Company.
To the Knowledge of the Sellers, there has been no actual or suspected privacy breach of any PII that is owned, used, stored, received,
or controlled by or on behalf of the Company. No claims are pending or, to the Knowledge of the Sellers, threatened or likely to
be asserted against the Company by any Person alleging a violation of any applicable Laws or rights relating to privacy, PII, or
any other confidentiality rights under any applicable U.S. Laws, policies or procedures. To the Knowledge of the Sellers, the consummation
of the transactions contemplated hereby will not breach or otherwise cause any violation of any applicable Laws relating to privacy
or security, or of the privacy policies or procedures of the Company.

 

(q)       The
Company owns, leases or licenses software, hardware, databases, computer equipment and other information technology comprising
its Internal Systems. The Company has taken reasonable, necessary and appropriate steps to preserve the availability, security
and integrity of its Internal Systems and the data and information stored on its Internal Systems. The Internal Systems operate
and perform in all material respects in a manner that permits the Company to conduct the Business as currently conducted, and the
Company has purchased or otherwise lawfully acquired a sufficient number of licenses for all material third party software used
by the Company. The documentation and the source code with its embedded commentary and descriptions, the specifications and the
other informational materials which describe the operation, functions and technical characteristics applicable to the Internal
Systems are complete in all material respects and sufficient to permit the Company to support and maintain the Proprietary Software
Products and operations of the Business. With respect to the Internal Systems: (i) there have been no successful or, to the Knowledge
of the Sellers, there has not been any material malfunction thereof that has not been remedied or replaced in all material respects,
or any material unplanned downtime or material service interruption thereof; (ii) the Company has implemented or is in the process
of implementing (or in the exercise of reasonable business judgment has determined that implementation is not yet in the best interest
of the Company) in a timely manner any and all security patches or security upgrades that are generally available therefor; and
(iii) to the Knowledge of the Sellers, no third party providing services to the Company has failed to meet any service obligations
with respect to the Internal Systems. The Company has implemented reasonable backup and disaster recovery technology processes
substantially consistent with industry practices and has tested such processes for effectiveness.

 

 

 

    	 	16	 

     

    

 

Section 3.11.Contracts.

 

(a)       Schedule
M sets forth all of the Contracts to which the Company is a party or by which it or any of its assets are bound of the types
described below:

 

(i)       Contracts
relating to employment or compensation or with any current or former officer, director or employee of the Company;

 

(ii)       Contracts
entered into within the last five years relating to the acquisition or disposition of any equity interest in or assets of, any
Person;

 

(iii)       Contracts
limiting the ability of the Company to engage in any line of business or to compete with any Person or to conduct business in any
geographical area;

 

(iv)       Contracts
relating to any indebtedness of the Company and Contracts under which the Company has imposed or incurred a Lien on any of its
assets;

 

(v)       Contracts
relating to any loan or investment by the Company or any guarantee of any obligation of any other Person;

 

(vi)       Contracts
with any Governmental Body; and

 

(vii)       All
other Contracts which involve the receipt or payment of an amount in excess of $10,000 or any 12-month period.

 

(b)       Complete
copies of the items required to be set forth in Schedule M have previously been provided to Purchaser by Sellers. The Company
is not in default, and no event has occurred which, with the giving of notice or the passage of time or both, would constitute
a default, under any such Contract or any other obligation owed by the Company and, to the Knowledge of the Sellers, no event has
occurred which, with the giving of notice or the passage of time or both, would constitute a default by any other party to any
such Contract. Each of the Contracts disclosed in Schedule M is in full force and effect, is valid and enforceable in accordance
with its terms and, to the Knowledge of the Sellers, is not subject to any claims, charges, setoffs or defenses. There are no disputes
pending or threatened under any such Contract. The Company and, to the Knowledge of the Sellers, each other party thereto is in
compliance with all of its obligations under each such Contract.

 

 

 

    	 	17	 

     

    

 

Section 3.12.Employee
Benefits. There are no Company “employee benefit plans” as defined in Section 3(3) of the Employee Retirement Income
Security Act of 1974, as amended (“ERISA”), and any other pension plans or employee benefit agreements, arrangements,
programs or payroll practices (including severance pay, other termination benefits or compensation, vacation pay, salary, company
awards, stock option, stock purchase, salary continuation for disability, sick leave, retirement, deferred compensation, bonus
or other incentive compensation, stock purchase arrangements or policies, hospitalization, medical insurance, life insurance and
scholarship programs) (whether funded or unfunded, written or oral, qualified or nonqualified), sponsored, maintained or contributed
to or required to be contributed to by the Company or by any trade or business, whether or not incorporated, that together with
the Company would be deemed a “single employer” within the meaning of Section 4001 of ERISA (a “Company ERISA
Affiliate”) for the benefit of any employee, leased employee, director, officer, shareholder or independent contractor
(in each case either current or former) of the Company or any Company ERISA Affiliate (“Employee Benefit Plans”).
None of the Company, any of its Affiliates or any Company ERISA Affiliate has ever participated in, been required to contribute
to, or otherwise been required to participate in any Multiemployer Plan or any Multiple Employer Plan. No Employee Benefit Plan
is or at any time was a “defined benefit plan” as defined in Section 3(35) of ERISA or a pension plan subject to the
funding standards of Section 302 of ERISA or Section 412 of the Code. Neither the Company, nor any of its Affiliates, nor any Company
ERISA Affiliate has ever participated in, been required to contribute to, or otherwise been required to participate in any plan,
program or arrangement subject to Title IV of ERISA. No Employee Benefit Plan is a multiple employer welfare arrangement as defined
in Section 3(40) of ERISA.

 

Section 3.13.Labor.

 

(a)       There
are no Legal Proceedings against the Company pending or, to the Knowledge of the Sellers, threatened which would reasonably be
expected to be brought or filed, with any public or Governmental Body based on, arising out of, in connection with, or otherwise
relating to the application or recruitment for employment, employment or termination of employment of any individual or group by
the Company.

 

(b)       To
the Knowledge of the Sellers, no executive or employee currently has any plans to terminate employment with the Company independently
of or as a result of the transactions contemplated by this Agreement.

 

(c)       The
Company is and has been in compliance with all applicable Laws pertaining to employment and employment practices to the extent
they relate to the employees of the Company, including all Laws relating to labor relations, equal employment opportunities, fair
employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits,
immigration, wage and hours, overtime compensation, child labor, health and safety, workers’ compensation, uniformed services
employment, whistleblowers, leaves of absence and unemployment insurance. All individuals characterized and treated by the Company
as consultants or contractors are properly treated as independent contractors under all applicable Laws. There are no Legal Proceedings
pending against the Company or, to the Knowledge of the Sellers, threatened to be brought or filed, by or with any Governmental
Body or arbitrator in connection with the employment of any current or former employee, consultant or independent contractor, including
any claim relating to unfair labor practices, employment discrimination, harassment, retaliation, equal pay or any other employment
related matter arising under applicable Laws. There are no internal complaints or reports by any current or former employee, consultant
or independent contractor pursuant to the anti-harassment policy of the Company that are pending or under investigation.

 

 

 

    	 	18	 

     

    

 

(d)       The
provisions of WARN have not been applicable to the Company and the Company has no plans to undertake any action in the future that
would trigger WARN.

 

(e)       All
employees of the Company are residing and/or working in the United States (i) free of any restrictions or limitations on their
ability to accept employment lawfully in the United States and (ii) in compliance with all applicable Laws relating to immigration
and naturalization. No Legal Proceeding has been filed or commenced against the Company or, to the Knowledge of the Sellers, any
employees thereof, that (a) alleges any failure so to comply or (b) seeks removal, exclusion or other restrictions on such employee’s
ability to reside and/or accept employment lawfully in the United States and/or the continued ability of the Company to sponsor
employees for immigration benefits and, to the Knowledge of the Sellers, there is no reasonable basis for any of the foregoing.
To the Knowledge of the Sellers, there is no reasonable basis to believe that any employee of the Company will not be able to continue
to so reside and/or accept employment lawfully in the United States in accordance with all such Laws. The Company maintains adequate
internal systems and procedures to provide reasonable assurance that all employee hiring is conducted in compliance with all applicable
Laws relating to immigration and naturalization. No audit, investigation or other Legal Proceeding has been commenced against the
Company at any time with respect to its compliance with applicable Laws relating to immigration and naturalization in connection
with its hiring practices.

 

Section 3.14.Compliance
with Laws; Permits.

 

(a)       The
Company is, and has at all times been, in compliance with all Laws applicable to it or the operation, use, occupancy or ownership
of its assets or properties or the conduct of the Business including, without limitation, the applicable standards for Privacy
or Security of Identifiable Health Information promulgated pursuant to the Health Insurance Portability and Accountability Act
of 1996, as amended, and the Standards for Privacy of Individually Identifiable Health Information, 45 C.F.R. Parts 160-164, the
Standards for Security of Electronic Protected Health Information, 45 C.F.R. Parts 160, 162 and 164, and the implementing regulations
thereunder, and the Health Information Technology for Economic and Clinical Health Act (“HITECH”) (collectively,
“HIPAA”). The Company has not received written notice from any Governmental Body of, and Sellers have no Knowledge
of, any failure to comply with any Law. There is no investigation by a Governmental Body pending against or, to the Knowledge of
the Sellers, threatened against the Company.

 

(b)       Schedule
L contains a complete and accurate list of each Permit that is held by the Company or that otherwise relates to the Business.
Each Permit listed or required to be listed on Schedule K is valid and in full force and effect. Further:

 

(i)       the
Company is, and has been, in full compliance with all of the terms and requirements of each Permit identified or required to be
identified;

 

 

 

    	 	19	 

     

    

 

(ii)       no
event has occurred or circumstance exists that may (with or without notice or lapse of time) (A) constitute or result directly
or indirectly in a violation of or a failure to comply with any term or requirement of any Permit identified or required to be
identified or (B) result directly or indirectly in the revocation, withdrawal, suspension, cancellation or termination of, or any
modification to, any Permit identified or required to be identified;

 

(iii)       the
Company has not received any notice or other communication (whether oral or written) from any Governmental Body or any other Person
regarding (A) any actual, alleged, possible or potential violation of or failure to comply with any term or requirement of any
Permit or (B) any actual, proposed, possible or potential revocation, withdrawal, suspension, cancellation, termination of or modification
to any Permit; and

 

(iv)       all
applications required to have been filed for the renewal of the Permits identified or required to be identified in Schedule
L have been duly filed on a timely basis with the appropriate Governmental Bodies, and all other filings required to have been
made with respect to such Permits have been duly made on a timely basis with the appropriate Governmental Bodies.

 

The Permits identified
in Schedule L collectively constitute all of the Permits necessary to enable the Company to lawfully conduct and operate
the Business and to own and use its assets in the manner in which it currently owns and uses such assets.

 

(c)       There
is no Legal Proceeding pending or threatened against the Company before any court or other governmental Body or any arbitral tribunal,
nor is there any basis for any such Legal Proceeding.

 

Section 3.15.Environmental
Matters.

 

(a)       The
operations of the Company are currently and have been in compliance with all applicable Environmental Laws and all licenses and
permits issued pursuant to Environmental Laws or otherwise (“Environmental Permits”).

 

(b)       The
Company has obtained and currently maintains all Environmental Permits required under all applicable Environmental Laws necessary
to operate the Business.

 

(c)       The
Company is not the subject of any outstanding written Order or Contract with any Governmental Body or other Person respecting any
Environmental Laws or any Release or threatened Release of a Hazardous Material.

 

(d)       The
Company has not received any written communication alleging either that it may be in violation of any Environmental Law or Environmental
Permit or that it may have any Liability under any Environmental Law.

 

(e)       The
Company has not incurred, assumed or undertaken any contingent Liability in connection with any Release of any Hazardous Materials
into the indoor or outdoor environment (whether on-site or off-site) and there are no facts, circumstances or conditions relating
to, arising out of or attributable to it that could give rise to Liability under Environmental Laws.

 

 

 

    	 	20	 

     

    

 

(f)       To
the Knowledge of the Sellers, there is not located at any of the properties of the Company any (i) underground storage tanks, (ii)
asbestos or asbestos-containing material, (iii) equipment containing polychlorinated biphenyls, (iv) lead-based paint, or (v) mold;
and

 

(g)       Sellers
have delivered to Purchaser all environmentally related audits, studies, reports, analyses, and results of investigations that
have been performed within the previous five years with respect to the currently or previously owned, leased or operated properties
of the Company.

 

Section 3.16.Insurance.
Schedule J includes a correct and complete list and description, including policy number, coverage and deductible, of all
insurance policies owned by the Company, complete copies of which policies have previously been delivered to Purchaser by Sellers.
Such policies are in full force and effect, all premiums due thereon have been paid and the Company is not in default thereunder.
Such insurance policies are of the type and in the amounts customarily carried by Persons conducting a business similar to the
Business and are sufficient for compliance with all applicable Laws and Contracts to which the Company is a party or by which it
is bound. The Company has not received any notices of cancellation or intent to cancel or increase or intent to increase premiums
with respect to such insurance policies nor is there any basis for any such action. There are no pending claims or any claims in
the past five (5) years with any insurance company by the Company and there were no instances within the previous five (5) years
of a denial of coverage of the Company by any insurance company.

 

Section 3.17.Receivables;
Payables.

 

(a)       The
accounts receivable and notes receivable of the Company reflected in the Balance Sheet and arising after the date thereof have
arisen in bona fide arm’s-length transactions in the ordinary and usual course of business consistent with past custom and
practice, and, subject to the allowance for doubtful accounts set forth in the Balance Sheet, all such receivables are valid, collectible
and binding obligations of the account debtors without any counterclaims, setoffs or other defenses thereto. All such reserves,
allowances and discounts were and are adequate and consistent in extent with the reserves, allowances and discounts previously
maintained by the Company in the ordinary and usual course of business consistent with past custom and practice and determined
in accordance with GAAP. A complete list of all accounts receivable and notes receivable of the Company as of the date hereof is
included Schedule C.

 

(b)       All
accounts payable of the Company reflected on the Balance Sheet and arising after the date thereof are the result of bona fide transactions
in the ordinary course of business and have been paid or are not yet due and payable, except for accounts payable that are being
disputed in good faith in an appropriate manner and for which there are adequate reserves on the Balance Sheet, or, with respect
to accounts payable arising after the Balance Sheet Date, on the accounting records of the Company.

 

 

 

    	 	21	 

     

    

 

Section 3.18.Absence
of Certain Business Practices. The Company has not, and no Seller, no Affiliate or agent of the Company or any Seller, and
no other Person acting on behalf of or associated with any Seller or the Company, acting alone or together, has (a) received, directly
or indirectly, any rebates, payments, commissions, promotional allowances or any other economic benefits, regardless of their nature
or type, from any customer, supplier or employee or agent of any customer or supplier; or (b) directly or indirectly given or agreed
to give any money, gift or similar benefit to any customer, supplier or employee or agent of any customer or supplier, any official
or employee of any government (domestic or foreign), or any political party or candidate for office (domestic or foreign), or other
Person who was, is or may be in a position to help or hinder the business of the Company (or assist the Company in connection with
any actual or proposed transaction), in each case which (i) may subject the Company to any damage or penalty in any civil, criminal
or governmental litigation or proceeding, (ii) if not given in the past, may have had an adverse effect on the assets, Business,
or operations of the Company, or (iii) if not continued in the future, may adversely affect the assets, business, or operations
of the Company.

 

Section 3.19.Business
Continuity. None of the computer software, computer hardware (whether general or special purpose), telecommunications capabilities
(including all voice, data and video networks) and other similar or related items of automated, computerized, and/or software systems
and any other networks or systems and related services that are used by or relied on by the Company in the conduct of the Business
(collectively, the “Systems”) have experienced bugs, failures, breakdowns, or continued substandard performance
in the past twelve (12) months that has caused any substantial disruption or interruption in or to the use of any such Systems
by the Company.

 

Section 3.20.Bank
Accounts; Powers of Attorney. Set forth in Schedule N is the following information:

 

(a)       with
respect to any borrowing or investment arrangements, deposit or checking accounts or safety deposit boxes of the Company, the name
of the financial institution, the type of account and the account number; and

 

(b)       the
name of each Person holding a general or special power of attorney from or with respect to the Company and a description of the
terms of each such power.

 

Section 3.21.Brokers
Fees. Except for Technology Park.Com, the Company does not have any Liability to pay any fees or commissions to any investment
banker, broker, finder, agent or any other similar Person with respect to the transactions contemplated by this Agreement. The
arrangements with Technology Park.Com have been disclosed to the Purchaser in writing as set forth in Schedule A as part
of the Creditor & Lender Report.

 

Section 3.22.No
Misrepresentation. No representation or warranty of the Company or Sellers contained in this Agreement, any Transaction Document
or any certificate or other instrument furnished to Purchaser or Rennova connection herewith contains any untrue statement of a
material fact or omits to state a material fact necessary to make the statements contained herein or therein not misleading.

 

 

 

    	 	22	 

     

    

 

ARTICLE
IV

REPRESENTATIONS AND WARRANTIES OF PURCHASER AND RENNOVA

 

Purchaser and Rennova,
jointly and severally, represent and warrant to Sellers as follows:

 

Section 4.1.Organization.
Purchaser is a corporation duly organized under the Laws of the State of Florida and its status is active. Rennova is a corporation
duly organized, validly existing and in good standing under the Laws of the State of Delaware. Each of the Purchaser and Rennova
has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business. Each of
the Purchaser and Rennova is duly qualified or authorized to do business as a foreign corporation and is in good standing under
the Laws of each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification
or authorization.

 

Section 4.2.Authorization
and Enforceability. The execution, delivery and performance of this Agreement and Transaction Documents to which Purchaser
or Rennova is a party have been duly authorized by all necessary action by or on behalf of Purchaser or Rennova. Each of Purchaser
and Rennova has full power and authority to execute and deliver this Agreement and each other Transaction Document to which it
is a party, and to perform its obligations hereunder and thereunder. This Agreement and each Transaction Document to which Purchaser
or Rennova is or will be a party has been or will be duly and validly executed and delivered and constitutes the valid and legally
binding obligation of Purchaser or Rennova, enforceable against Purchaser or Rennova in accordance with its terms, subject to applicable
bankruptcy, insolvency, reorganization, moratorium and similar Laws affecting creditors’ rights and remedies generally and
subject, as to enforceability, to general principles of equity (regardless of whether enforcement is sought in a proceeding at
Law or in equity).

 

Section 4.3.Conflicts;
Consent of Third Parties. Neither the execution and the delivery by Purchaser or Rennova of this Agreement and the other Transaction
Documents to which it is a party, nor the consummation of the transactions contemplated hereby and thereby on the part of Purchaser
or Rennova, will, with or without the passage of time or the giving of notice (a) conflict with, or result in the breach of, any
provision of the Governing Documents of Purchaser or Rennova or (b) conflict with, violate, result in the breach or termination
of, or constitute a default under, result in an acceleration of, or create in any party the right to accelerate, terminate, modify
or cancel, any Contract to which Purchaser or Rennova is a party or by which Purchaser or Rennova or its properties or assets are
bound.

 

Section 4.4.Brokers
Fees. Neither Purchaser nor Rennova has any Liability to pay any fees or commissions to any broker, finder, agent or any other
similar Person with respect to the transactions contemplated by this Agreement.

 

Section 4.5.No
Proceedings. No suit, action or other proceeding is pending before any Governmental Body seeking to restrain or prohibit Purchaser
or Rennova from entering into this Agreement or to prohibit the Closing or the performance of any other obligation hereunder.

 

Section 4.6.Investment
Purpose. Purchaser is acquiring the Purchased Shares solely for the purpose of investment and not with a view to, or for offer
or sale in connection with, any distribution thereof. Purchaser acknowledges that the Purchased Shares are not registered under
the Securities Act, and that the Purchased Shares may not be transferred or sold except pursuant to the registration provisions
of the Securities Act or pursuant to an applicable exemption therefrom and subject to Blue Sky Laws.

 

 

 

    	 	23	 

     

    

 

Section 4.7.Preferred
Shares. Upon issuance pursuant to the terms of this Agreement, the Series F Preferred will be duly authorized, validly issued,
fully paid and non-assessable.

 

ARTICLE
V

COVENANTS

 

Section 5.1.Commercially
Reasonable Efforts; Notices and Consents.

 

(a)       Each
of the Parties shall use its commercially reasonable efforts to take all action required of it and to do all things necessary,
proper or advisable on its part in order to consummate and make effective the transactions contemplated by this Agreement and each
of the Transaction Documents.

 

(b)       Each
of the Parties shall give any notices to, make any filings with, and use their commercially reasonable efforts to obtain any Consents
which are required to be given, made or obtained by it in connection with consummation of the transactions contemplated by this
Agreement.

 

(c)       From
the date hereof until the Closing, the Sellers shall promptly notify Purchaser in writing of:

 

(i)       any
fact, circumstance, event or action the existence, occurrence or taking of which (A) has had, or could reasonably be expected to
have, individually or in the aggregate, a Company Material Adverse Effect, (B) has resulted in, or could reasonably be expected
to result in, any representation or warranty made by Sellers hereunder not being true and correct or (C) has resulted in, or could
reasonably be expected to result in, the failure of any of the conditions set forth herein to be satisfied;

 

(ii)       any
notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with
the transactions contemplated by this Agreement;

 

(iii)       any
notice or other communication from any Governmental Body in connection with the transactions contemplated by this Agreement; and

 

(iv)       any
Legal Proceedings commenced or, to Sellers’ Knowledge, threatened against, relating to or involving or otherwise affecting
Sellers or the Company that, if pending on the date of this Agreement, would have been required to have been disclosed pursuant
to this Agreement or that relates to the consummation of the transactions contemplated by this Agreement.

 

 

 

    	 	24	 

     

    

 

Purchaser’s receipt
of information pursuant to this Agreement shall not operate as a waiver or otherwise affect any representation, warranty or agreement
given or made by Sellers, and shall not be deemed to amend or supplement the Schedules attached hereto.

 

Section 5.2.Access
to Information; Financial Statements.

 

(a)       From
the date hereof until the Closing, Sellers and the Company shall (i) afford Purchaser and its employees, agents, accountants and
legal and financial advisors (collectively, the “Purchaser’s Agents”) with access, during normal business
hours, to the offices, plants, warehouses, properties, and Books and Records of the Company, and (ii) furnish to Purchaser’s
Agents such additional financial and operating data and other information regarding the operations of the Company as Purchaser
may from time to time request. Sellers and the Company shall facilitate Purchaser’s contact and communication with the employees
and personnel of the Company, and the customers, suppliers, vendors and distributors of the Business, all as requested upon reasonable
notice by Purchaser to the Sellers and during normal business hours after the date hereof. Sellers and the Company shall direct
the employees and personnel of the Company to cooperate with Purchaser in connection with the foregoing. From the date hereof through
the Closing, Sellers and the Company shall use good faith efforts to operate the Business in such a manner as to achieve a smooth
transition consistent with the mutual business interests of Sellers and Purchaser.

 

(b)       From
the date hereof until the Closing, the Sellers shall, as soon as practicable and in any event within fifteen (15) days after the
end of each fiscal month of the Company, deliver to Purchaser the internally prepared consolidated financial statements of the
Company as of the end of such fiscal month, for such fiscal month and for the period from the beginning of the then-current fiscal
year to the end of such fiscal month.

 

Section 5.3.Operation
of Business.

 

Except as contemplated
by this Agreement, during the period from the date of this Agreement to the Closing, the Company shall conduct its operations in
the ordinary course of business consistent with past practice and in compliance with all applicable Laws, to the extent consistent
therewith, use its best efforts to preserve intact its current business organization, keep its physical assets in good working
condition, keep available the services of its current officers and employees and preserve its relationships with Governmental Bodies,
customers, suppliers and others having business dealings with it to the end that its goodwill and ongoing business shall not be
impaired in any material respect. Without limiting the generality of the foregoing, prior to the Closing, the Company shall not,
without the written consent of Purchaser, take any of the following actions:

 

(a)       declare
or pay any dividends or distributions on or in respect of any of the capital stock or other securities of the Company or redeem,
purchase or acquire any capital stock or other securities of the Company or make any other payment to or on behalf of any shareholder
or other equity holder of the Company or any Affiliate thereof;

 

(b)       make
any change in the rate of compensation, commission, bonus or other direct or indirect remuneration payable, or pay or agree or
orally promise to pay, conditionally or otherwise, any bonus, incentive, retention or other compensation, retirement, welfare,
fringe or severance benefit or vacation pay, to or in respect of any director, officer, employee, distributor or agent of the Company,
other than increases in the ordinary course of business consistent with past practice in the base wages or salaries of employees
of the Company;

 

 

 

    	 	25	 

     

    

 

(c)       enter
into or amend any employment, deferred compensation, severance or similar contract;

 

(d)       materially
change any of its accounting or Tax reporting principles, methods or policies, settle any Tax controversy, amend any Tax Return,
or make any material Tax election by or with respect to the Company;

 

(e)       except
for the transactions contemplated by this Agreement, enter into or amend any other transaction or Contract other than in the ordinary
course of business consistent with past practice;

 

(f)       hire
any employees or engage any independent contractors other than in the ordinary course of business consistent with, and at a level
consistent with, past practice;

 

(g)       breach
any Contract;

 

(h)       make
any loans, advances or capital contributions to, or investments in, any Person;

 

(i)       mortgage,
pledge or subject to any Lien any of its assets, or acquire any assets or sell, assign, transfer, convey, lease or otherwise dispose
of any assets of the Company except for assets acquired or sold, assigned, transferred, conveyed, leased or otherwise disposed
of in the ordinary course of business consistent with past practice;

 

(j)       cancel
or compromise any debt or claim or amend, cancel, terminate, relinquish, waive or release any Contract or right except in the ordinary
course of business consistent with past practice and which, in the aggregate, are not material to the Company;

 

(k)       enter
into or amend any Contract or transaction with any of its Affiliates or pay any fees, expenses or other amounts to any Affiliate
of the Company;

 

(l)       make
or commit to make any capital expenditures or capital additions or improvements (i) in excess of $2,500 individually or $5,000
in the aggregate or (ii) outside the ordinary course of business consistent with past practices;

 

(m)       enter
into any prepaid services transactions with any of its customers or otherwise accelerate revenue recognition or the sales of its
services for periods prior to the Closing;

 

(n)       amend
any of its Governing Documents;

 

(o)       adopt
any plan of merger, consolidation, reorganization, liquidation or dissolution or file a petition in bankruptcy under any provisions
of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law or other
agreement with respect to the sale of its assets, securities or Business;

 

 

 

    	 	26	 

     

    

 

(p)       issue
any equity or debt securities or any security exercisable or exchangeable for or convertible into equity securities of the Company,
or incur any Indebtedness or other Liabilities (other than in the ordinary course of business consistent with past practices);

 

(q)       (i)
discharge, repay, amend, modify, make payment on, cancel or compromise any Indebtedness, or discharge or satisfy any Lien, or (ii)
engage in any transaction or provide any consideration relating to the release, modification or diminution of any guarantee, bond,
surety or other obligation of any Seller or any Affiliate thereof;

 

(r)       take
any action or omit to take any action that is reasonably likely to result in any of the conditions set forth herein not being satisfied;
or

 

(s)       enter
into any contracts or commitments to do or perform in the future any actions referred to in this Section 5.3.

 

Section 5.4.Further
Assurances; Litigation Support.

 

(a)       If
any further action is necessary or desirable to carry out the purposes of this Agreement, each of the Parties will take such further
action (including the execution and delivery of such further instruments and documents) as any other Party reasonably may request;
provided, however, that neither Purchaser nor Rennova shall be required to incur any out-of-pocket expense in connection therewith
if it may be entitled to indemnity in connection therewith. Sellers and the Company shall cooperate with Purchaser to encourage
each lessor, licensor, customer, supplier, or other business associate of the Company to maintain the same business relationships
with the Company after the Closing as it maintained with the Company prior to the Closing, at Purchaser’s sole cost and expense.

 

(b)       Following
the Closing, in the event and for so long as either Purchaser or Rennova actively is involved in, contesting or defending against
any Legal Proceeding in connection with any fact, situation, circumstances, status, condition, activity, practice, plan, occurrence,
event, incident, action, Tax matter, failure to act, or transaction involving the Company, each Seller shall cooperate reasonably
with Purchaser or Rennova and such Party’s counsel in such involvement, contest or defense, and provide such testimony and
access to their books and records as shall be reasonably necessary in connection with such contest or defense, all at the sole
reasonable cost and expense of Purchaser (unless Purchaser or Rennova is entitled to indemnification therefor hereunder).

 

Section 5.5.Names
and Logos. From and after the Closing, Sellers will not, and will cause their respective Affiliates not to, use any names or
logos incorporating or similar to “Genomas” or any derivatives thereof or any other trade name used in the Business.

 

Section 5.6.Mail;
Payments; Receivables. From and after the Closing, each Seller agrees to refer to Purchaser all customer, supplier, employee
or other inquiries or correspondence relating to the Company and the conduct of the Business after the Closing Date. From and after
the Closing, each Seller further agrees to remit to Purchaser all payments and invoices received by him or it or his or its Affiliates
that relate to the Company (including accounts receivable) or the conduct of the Business after the Closing Date within five (5)
Business Days after his or its receipt thereof.

 

 

 

    	 	27	 

     

    

 

Section 5.7.Public
Announcements; Confidentiality.

 

(a)       Unless
otherwise required by applicable Law, no Seller shall, and each Seller shall cause his Affiliates, agents, representatives and
professionals not to, and, prior to the Closing, the Company shall not, make any disclosure or public announcements in respect
of this Agreement or the transactions contemplated hereby (including price and terms) or otherwise communicate with any news media
without the prior written consent of Purchaser.

 

(b)       From
and after the Closing, each Seller shall, and shall cause his or its respective Affiliates to, hold, and shall use his or its best
efforts to cause his or its or their respective representatives to hold, in confidence (and not disclose or provide access to any
other Person) any and all information, whether written or oral, concerning the Company or the Business, except to the extent that
such Seller can show that such information (i) is generally available to and known by the public through no fault of any Seller
or any of his or its respective Affiliates or representatives; or (ii) is lawfully acquired by such Seller or any of his or its
respective Affiliates or representatives from and after the Closing from sources unrelated to Purchaser, the Company or any Seller
which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If any Seller or any
of his or its respective Affiliates or representatives are compelled to disclose any information by judicial or administrative
process or by other requirements of Law, Sellers shall promptly notify Purchaser in writing and shall disclose only that portion
of such information which Sellers are advised by their counsel in writing is legally required to be disclosed; provided, however,
that each Seller shall use best efforts to obtain an appropriate protective order or other reasonable assurance that confidential
treatment will be accorded such information.

 

Section 5.8.Tax
Covenants.

 

(a)       Purchaser
and Rennova, on the one hand, and Sellers, on the other, agree, for all Tax purposes, to report the transactions effected pursuant
to the Transaction Documents in a manner consistent with the terms of this Agreement and none of them shall take a position on
any Tax return, before any Tax authority or in any judicial proceeding that is, in any manner, inconsistent with such treatment
without the consent of the others or unless specifically required pursuant to a determination by an applicable Tax authority. The
Parties shall promptly advise one another of the existence of any Tax audit, controversy or litigation related to the Tax treatment
of the transactions effected pursuant to the Transaction Documents.

 

(b)       Notwithstanding
anything to the contrary set forth herein, any income Tax attributable to the sale or transfer of the Purchased Shares by the Sellers
shall be paid by Sellers. Any documentary stamp Tax due and payable solely due to the sale or transfer of the Purchased Shares
by the Sellers or the issuance by Rennova of the Series F Preferred shall be paid by the Purchaser.

 

 

 

    	 	28	 

     

    

 

(c)       For
purposes of determining the Taxes of the Company through a particular date under all provisions of this Agreement, in the case
of any Tax period that includes (but does not end on) the Closing Date (a “Straddle Period”), the amount of
any Taxes based on or measured by income or receipts for the portion of the period ending on the Closing Date shall be determined
based on an interim closing of the books as of the close of business on the Closing Date (and for such purpose, the Taxable period
of any partnership or other pass-through entity in which the Company holds a beneficial interest shall be deemed to terminate at
such time) and the amount of other Taxes for a Straddle Period which relates to the portion of the period ending on the Closing
Date shall be deemed to be the amount of such Tax for the entire Taxable period multiplied by a fraction the numerator of which
is the number of days in the Taxable period ending on the Closing Date and the denominator of which is the total number of days
in such Straddle Period.

 

(d)       The
Parties will provide each other with such reasonable cooperation and information as any of them reasonably may request of another
in filing any Tax Return or conducting any audit, investigation or other proceeding in respect of Taxes. Each such Party will make
its employees and representatives available on a mutually convenient basis to provide explanations of any documents or information
provided hereunder. Each such Party will make available all Tax Returns, schedules and work papers and all other records or documents
relating to Tax matters of the Company in their possession or control, including audit reports received from any Tax authority
relating to any Tax Return of the Company, until the expiration of the statute of limitations of the respective Tax periods to
which such Tax Returns and other documents relate. Any non-public information obtained from the Parties under this Article will
be kept confidential, except as otherwise required by applicable Law.

 

Section 5.9.Exclusive
Dealing. During the period from the date hereof through the Closing Date or the earlier termination of this Agreement, Sellers
and the Company shall not, directly or indirectly, and shall cause their respective officers, directors, employees, agents, consultants,
representatives, advisors and Affiliates to not, directly or indirectly:

 

(a)       solicit,
facilitate or encourage the initiation of any inquiry, proposal or offer from any Person (other than Purchaser or its Affiliates)
relating to a possible Acquisition Transaction;

 

(b)       participate
in any discussions or negotiations or enter into any agreement with, or provide any non-public information to, any Person (other
than Purchaser or its Affiliates) relating to or in connection with a possible Acquisition Transaction; or

 

(c)       accept
any proposal or offer from any Person (other than Purchaser or its Affiliates) relating to a possible Acquisition Transaction.

 

Sellers and the Company
further agree that they shall, prior to the earlier of the Closing or the termination of this Agreement in accordance with its
terms, promptly (and in no event later than 24 hours after receipt thereof) notify Purchaser orally and in writing of any inquiry,
proposal or offer relating to a possible Acquisition Transaction, including the identity of the Person making or submitting such
inquiry, proposal or offer, and the terms thereof (including a copy of any written inquiry, proposal or offer) that is received
by the Company or any Seller or any representative thereof from the date of this Agreement through the Closing Date.

 

 

 

    	 	29	 

     

    

 

Section 5.10.Non-Competition;
Non-Solicitation.

 

(a)       Each
Seller acknowledges that he or it is familiar with the trade secrets and other confidential information of the Company. Therefore,
and in further consideration of the compensation to be paid to Sellers hereunder, each Seller agrees to the covenants set forth
in this Agreement and acknowledges that Purchaser and Rennova would not have entered into this Agreement but for Sellers’
agreement to the restrictions set forth in this Agreement.

 

(b)       For
a period of two (2) years from and after the Closing Date, no Seller shall, directly or indirectly, own, operate, lease, manage,
control, engage in, invest in, lend to, own any debt or equity security of, permit his or its name to be used by, act as consultant
or advisor to, render services for (alone or in association with any person, firm, corporate or other business organization) or
otherwise assist in any manner any Person in any genetics diagnostics business; provided, however, that nothing herein
shall prohibit a Seller from (i) being a beneficial owner of less than two percent (2%) of the outstanding stock of any publicly-traded
corporation or (ii) performing any of the above acts in any business that is not competitive with the Business.

 

(c)       For
a period of three (3) years from and after the Closing Date, no Seller shall directly or indirectly: (i) induce or attempt to induce
any employee or consultant of the Company, Rennova or Purchaser (collectively, the “Company Parties”) to leave
the employ of, or engagement with, any of the Company Parties, or in any way interfere with the relationship between any of the
Company Parties and any employee or consultant thereof, (ii) hire or engage any person who is or was within two (2) years of the
Closing Date an employee or consultant of any of the Company Parties, or (iii) induce or attempt to induce any person or entity
who is or was within two (2) years a customer, supplier, licensee, licensor, franchisee or other business relation of any of the
Company Parties to cease doing business with any of the Company Parties, or in any way interfere with the relationship between
any such customer, supplier, licensee, licensor, franchisee or business relation and any of the Company Parties. No Seller shall
ever make or publish any statement or communication which is disparaging, negative or unflattering with respect to any of the Company
Parties, or any of their respective shareholders, officers, directors, employees or agents.

 

(d)       The
Parties hereto acknowledge and agree that Purchaser and each of its Affiliates, successors and assigns would suffer irreparable
harm from a breach of this Section 5.10 by any Seller and that money damages would not be an adequate remedy for any such breach.
Therefore, in the event a breach or threatened breach of this Section 5.10, Purchaser and each of its Affiliates or their respective
successors and assigns, in addition to other rights and remedies existing in their favor, shall be entitled to specific performance,
and injunctive and other equitable relief from a court of competent jurisdiction in order to enforce, or prevent any violations
of, the provisions hereof (without posting a bond or other security and at the expense of the breaching Seller, including reasonable
attorneys’ fees and expenses). The restrictive covenants set forth herein shall be construed as agreements independent of
any other provision in this Agreement, and the existence of any claim or cause of action of any Seller against Purchaser or any
Affiliate, whether predicated upon this Agreement or otherwise, shall not constitute a defense to the enforcement by Purchaser
or any Affiliate of any restrictive covenant contained in this Agreement. Each of Purchaser and its Affiliates has fully performed
all obligations entitling it to the restrictive covenants set forth herein, and such restrictive covenants therefore are not executory
or otherwise subject to rejection under chapter 11 of title 11 of the United States Code.

 

 

 

    	 	30	 

     

    

 

(e)       If
the final judgment of a court of competent jurisdiction declares any term or provision of this Section 5.10 to be invalid or unenforceable,
the Parties agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the
scope, duration, or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable
term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of
the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified to cover the maximum duration,
scope or area permitted by Law. In addition, in the event of an alleged breach or violation by any Seller of this Section 5.10,
the three (3) year period described in clauses (b) and (c) above shall be tolled with respect to such Seller until such breach
or violation has been duly cured. Each Seller agrees that the restrictions contained in this Section 5.10 are reasonable.

 

Section 5.11.Resignations.
At the Closing, the Sellers shall deliver to Purchaser written resignations, effective as of the Closing Date, of the officers
and directors of the Company requested by Purchaser at least one (1) Business Day prior to the Closing.

 

Section 5.12.Tangible
Property. On or prior to the Closing Date, Sellers shall deliver to the Company all tangible property belonging to the Company
that is in their possession or under their control.

 

Section 5.13.Discharge
of Affiliate Obligations. Prior to the Closing, Sellers shall cause all Indebtedness, notes or other obligations of the Company
to any of Sellers or any of their respective Affiliates to be satisfied or cancelled, and Sellers shall cause all Indebtedness,
notes or other obligations of any of Sellers or any of their respective Affiliates to the Company to be satisfied or cancelled.

 

Section 5.14.Preferred
Stock. From or after the date hereof through the Closing Date or the earlier termination of this Agreement, no Seller shall
convert or request or vote to redeem any shares of Series A Preferred, Series B Preferred or Series C Preferred. All Sellers that
have options to purchase any security of the Company including under the 2004 Employee, Director and Consultant Stock Plan agree
that such options shall be cancelled at Closing for no consideration.

 

ARTICLE
VI

CLOSING CONDITIONS

 

Section 6.1.Conditions
to Obligation of Purchaser and Rennova. The obligation of Purchaser and Rennova to consummate the transactions contemplated
by this Agreement is subject to the fulfillment on or prior to the Closing Date of each of the following conditions, any one or
more of which (to the extent permitted by applicable Law) may be waived by Purchaser and Rennova (provided that no such waiver
shall be deemed to have cured any breach of any representation, warranty or covenant made in this Agreement):

 

 

 

    	 	31	 

     

    

 

(a)       The
representations and warranties of the Company and Sellers contained in this Agreement shall be true and correct in all material
respects (other than those representations and warranties that are qualified by materiality or Material Adverse Effect or similar
qualification, which shall be true and correct in all respects) both as of the date of this Agreement and as of the Closing, other
than such representations and warranties that are made as of a specified date, which representations and warranties shall be true
and correct as of such date. The covenants and agreements contained in this Agreement to be complied with by the Company and Sellers
at or before the Closing shall have been complied with in all material respects.

 

(b)       There
shall not have occurred a Company Material Adverse Effect.

 

(c)       No
temporary restraining order, preliminary or permanent injunction, cease and desist Order or other Order issued by any Governmental
Body, shall be in effect prohibiting or preventing the transactions contemplated by this Agreement.

 

(d)       The
Sellers shall have delivered the following:

 

(i)       a
certificate, dated as of the Closing Date, executed by the Sellers to the effect that the conditions have been satisfied;

 

(ii)       stock
certificates representing the Purchased Shares, free and clear of all Liens (other than any restrictions under the Securities Act
and Blue Sky Laws), each duly endorsed in blank or with duly executed stock powers attached, with all required stock transfer tax
stamps affixed thereto;

 

(iii)       a
certificate of the secretary of each Seller that is an entity and of the Company certifying to (A) the certificate of incorporation,
as amended (or similar incorporation or formation documents), of such entity, certified by the Secretary of State of the jurisdiction
in which each such entity is organized, as of a recent date, and stating that no amendments have been made to such certificate
of incorporation (or similar incorporation or formation documents) since such date, (B) all other Governing Documents of such entity,
(C) the adoption of resolutions by such entity approving the transactions contemplated by the Transaction Documents, and (D) the
incumbency of the officers signing the Transaction Documents on behalf of such entity (together with their specimen signatures);

 

(iv)       an
affidavit described in Section 1445(b)(2) of the Code from each Seller in form and substance reasonably satisfactory to Purchaser;

 

(v)       a
good standing certificate, as of a recent date, for each Seller that is an entity and the Company certified by the Secretary of
State of (A) the state of organization of such entity, and (B) each other jurisdiction in which such entity is qualified to do
business as a foreign entity;

 

(vi)       the
General Release, duly executed and delivered by each Seller;

 

 

 

    	 	32	 

     

    

 

(vii)       resignations
of the directors and officers of the Company pursuant to this Agreement;

 

(viii)       a
schedule of all accounts receivable of the Company as of the Business Day immediately prior to the Closing;

 

(ix)       evidence
satisfactory to the Purchaser and Rennova that all consents have been received and that all filings and notices have been made
or given in connection with this Agreement and the consummation of the transactions contemplated hereby; and

 

(x)       such
other documents, instruments or certificates as shall be reasonably requested by Purchaser, Rennova or their counsel.

 

(e)       The
Purchaser and Rennova shall have received the following:

 

(i)       the
Employment Agreement signed by Gualberto Ruaño;

 

(ii)       an
amended and restated Commercial Promissory Note, dated the Closing Date, in form satisfactory to Purchaser and Rennova and signed
by Phenomas, LLC, in the amount of $200,000 and the existing Commercial Promissory Note shall be marked as "Cancelled";
and

 

(iii)       documents
in form and substance acceptable to the Purchaser and Rennova cancelling any and all options to acquire any security of the Company,
including under the 2004 Employee, Director and Consultant Stock Plan, without any liability to the Company, the Purchaser or Rennova
and evidence that no options shall have been exercised between the date hereof and the Closing.

 

Section 6.2.Conditions
to Obligation of Sellers. The obligation of Sellers to consummate the transactions contemplated by this Agreement is subject
to the fulfillment on or prior to the Closing Date of each of the following conditions, any one or more of which (to the extent
permitted by applicable Law) may be waived by the Sellers (provided that no such waiver shall be deemed to have cured any breach
of any representation, warranty or covenant made in this Agreement):

 

(a)       The
representations and warranties of Purchaser and Rennova contained in this Agreement shall be true and correct in all material respects
(other than those representations and warranties that are qualified by materiality or Material Adverse Effect or similar qualification,
which shall be true and correct in all respects) both as of the date of this Agreement and as of the Closing, other than such representations
and warranties that are made as of a specified date, which representations and warranties shall be true and correct as of such
date. The covenants and agreements contained in this Agreement to be complied with by Purchaser and Rennova at or before the Closing
shall have been complied with in all material respects.

 

(b)       No
temporary restraining order, preliminary or permanent injunction, cease and desist Order or other order issued by any Governmental
Body shall be in effect prohibiting or preventing the transactions contemplated by this Agreement.

 

 

 

    	 	33	 

     

    

 

(c)       Rennova
shall have issued the Series F Preferred to the Sellers in accordance with the terms of this Agreement.

 

Section 6.3.Corporate
Approvals. The transaction shall be approved by the board of directors and stockholders of the Company, the Purchaser and Rennova
as may be required. For the period commencing upon the execution of this Agreement, the Company and the Sellers will not (and will
not authorize, permit or instruct any other person or entity on behalf of such party to) solicit, pursue, negotiate or enter into,
or provide any information with respect to or otherwise facilitate in any manner, a merger, consolidation, issuance or sale of
a material amount of assets or equity interests, tender or exchange offer, equity or debt financing or other similar transaction
involving such party, without the prior written consent of the Purchaser.

 

ARTICLE
VII

INDEMNIFICATION

 

Section 7.1.Indemnity
Obligations of Sellers.

 

Subject to the limitations
set forth herein, each Seller, jointly and severally, covenants and agrees to defend, indemnify and hold harmless Purchaser, Rennova
and their Affiliates (including, after the Closing, the Company) and the respective officers, directors, employees, agents, advisers
and representatives of the foregoing (collectively, and for the avoidance of doubt excluding any Seller or Affiliate thereof, the
“Purchaser Indemnitees”), from and against, and to pay or reimburse Purchaser Indemnitees for, any and all claims,
Liabilities, obligations, losses, fines, costs, diminution in value, proceedings or damages, including all reasonable fees and
disbursements of counsel incurred in the investigation or defense of any of the same or in asserting any of their respective rights
hereunder (collectively, “Losses”), based on, resulting from, arising out of or relating to:

 

(a)       any
misrepresentation or breach of any warranty of any Seller or the Company contained in this Agreement or in any certificate or agreement
delivered in connection herewith, it being understood that, in determining the existence of, and amount of any Losses in connection
with a claim under this Agreement, all representations and warranties shall be read without regard and without giving effect to
any materiality or Material Adverse Effect or similar qualification contained therein (as if such qualification were deleted from
such representation or warranty);

 

(b)       any
failure of any Seller or the Company to perform any covenant or agreement made or contained in this Agreement, or fulfill any obligation
in respect thereof;

 

(c)       any
Taxes of the Company with respect to any tax year or portion thereof ending on or before the Closing Date (or for any tax year
beginning before and ending after the Closing Date to the extent allocable to the portion of the period beginning before and ending
on the Closing Date);

 

(d)       any
Legal Proceeding brought by a third party based upon, arising out of or relating to the operations, properties, assets or obligations
of the Sellers, the Company or any of their respective Affiliates conducted, existing or arising on or prior to the Closing Date;

 

 

 

    	 	34	 

     

    

 

(e)       any
Indebtedness for Borrowed Money;

 

(f)       any
Seller Transaction Expenses or Change of Control Payments; and

 

(g)       any
amounts owed or payable to creditors or lenders other than as set forth in Schedule A.

 

Section 7.2.Indemnity
Obligations of Purchaser and Rennova. Purchaser and Rennova, jointly and severally, covenant and agree to defend, indemnify
and hold harmless Sellers from and against any and all Losses based on, resulting from, arising out of or relating to:

 

(a)       any
misrepresentation or breach of any warranty of Purchaser or Rennova contained in this Agreement or in any certificate or agreement
delivered in connection herewith, it being understood that, in determining the existence of, and amount of any Losses in connection
with a claim under this Agreement, all representations and warranties shall be read without regard and without giving effect to
any materiality or Material Adverse Effect or similar qualification contained therein (as if such qualification were deleted from
such representation or warranty); and/or

 

(b)       any
failure of Purchaser or Rennova to perform any covenant or agreement made or contained in this Agreement, or fulfill any other
obligation in respect thereof.

 

Section 7.3.Indemnification
Procedures.

 

(a)       Third
Party Claims. In the case of any claim asserted by a third party (a “Third Party Claim”) against a party
entitled to indemnification under this Agreement (the “Indemnified Party”), notice shall be given by the Indemnified
Party to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified
Party has actual knowledge of any claim as to which indemnity may be sought. If the Indemnifying Party provides a written notice
to the Indemnified Party within fifteen (15) days after its receipt of notice of such claim that it will indemnify and hold the
Indemnified Parties harmless from all Losses related to such Third Party Claim, the Indemnified Party shall permit the Indemnifying
Party (at the expense of such Indemnifying Party) to assume the defense of such Third Party Claim or any litigation with a third
party resulting therefrom; provided, however, that (i) the counsel for the Indemnifying Party who shall conduct the defense of
such claim or litigation shall be subject to the approval of the Indemnified Party, (ii) the Indemnified Party may participate
in such defense at such Indemnified Party’s expense, (iii) the failure by any Indemnified Party to give notice of a Third
Party Claim to the Indemnifying Party as provided herein shall not relieve the Indemnifying Party of its indemnification obligation
under this Agreement except and only to the extent that, as a result of such failure to give notice, the defense against such claim
is materially impaired, and (iv) the fees and expenses incurred by the Indemnified Party prior to the assumption of a Third Party
Claim hereunder by the Indemnifying Party shall be borne by the Indemnifying Party. Except with the prior written consent of the
Indemnified Party, no Indemnifying Party, in the defense of any Third Party Claim, shall consent to entry of any judgment or enter
into any settlement that provides for injunctive or other nonmonetary relief affecting the Indemnified Party or that does not include
as an unconditional term thereof the giving by each claimant or plaintiff to such Indemnified Party of a general release from any
and all liability with respect to such Third Party Claim. Notwithstanding anything herein to the contrary, the Indemnifying Party
shall not be entitled to assume control of the defense against a Third Party Claim if (1) the claim for indemnification relates
to or arises in connection with any criminal or quasi criminal proceeding, action, indictment, allegation or investigation; (2)
the claim seeks an injunction, specific performance or any other equitable or non-monetary relief against the Indemnified Party;
(3) the Indemnified Party reasonably believes an adverse determination with respect to the Third Party Claim would be materially
detrimental to or materially injure the Indemnified Party’s reputation or future business prospects; (4) the Indemnified
Party has been advised by counsel that a reasonable likelihood exists of a conflict of interest between the Indemnifying Party
and the Indemnified Party; or (5) the Indemnifying Party fails to vigorously prosecute or defend such claim. If the Indemnifying
Party does not accept the defense of a Third Party Claim within thirty (30) days after receipt of the written notice thereof from
the Indemnified Party described above, the Indemnified Party shall have the full right to defend against any such claim or demand.
In any event, the Indemnifying Party and the Indemnified Party shall reasonably cooperate in the defense of any Third Party Claim
and the records of each shall be reasonably available to the other with respect to such defense.

 

 

 

    	 	35	 

     

    

 

(b)       Non-Third
Party Claims. With respect to any claim for indemnification hereunder which does not involve a Third Party Claim, the Indemnified
Party will give the Indemnifying Party written notice of such claim. The Indemnifying Party may acknowledge and agree by notice
to the Indemnified Party in writing to satisfy such claim within fifteen (15) days of receipt of notice of such claim from the
Indemnified Party. If the Indemnifying Party shall dispute such claim, the Indemnifying Party shall provide written notice of such
dispute to the Indemnified Party within such fifteen (15) day period. If the Indemnifying Party shall fail to provide written notice
to the Indemnified Party within fifteen (15) days of receipt of notice from the Indemnified Party that the Indemnifying Party either
acknowledges and agrees to pay such claim or disputes such claim, the Indemnifying Party shall be deemed to have acknowledged and
agreed to pay such claim in full and to have waived any right to dispute such claim.

 

Section 7.4.Expiration
of Representations and Warranties. All representations and warranties contained in this Agreement shall survive the Closing
until the date which is twelve (12) months after the Closing Date; provided, however, that the representations and warranties stated
herein in Articles II and IV and Sections 3.1 and 3.3 shall survive indefinitely. All indemnification obligations shall survive
the Closing indefinitely. Notwithstanding the foregoing, all claims (and matters relating thereto) made in writing prior to the
expiration of the applicable survival period shall not thereafter be barred by the expiration of such survival period and shall
survive until finally resolved.

 

Section 7.5.Indemnification
Payments to Purchaser Indemnitees; Right of Set-Off.

 

(a)       Any
indemnification to which Purchaser Indemnitees are entitled under this Agreement as a consequence of any Losses they may suffer
shall be made in immediately available funds by wire transfer to a bank account to be designated by Purchaser. In the event that
any Purchaser Indemnitee seeks to recover against any Seller for any Loss, liability or other obligation pursuant to this Agreement
or otherwise in connection with this Agreement, and does not receive payment in cash from such Seller within 15 days of the demand
in writing therefor, Purchaser or such Purchaser Indemnitee shall have the right to recover such amount by set-off or cancellation
against: (i) any amount payable by Purchaser or any Affiliate to such Seller under the Employment Agreement; (ii) any amount payable
by Purchaser or any Affiliate to such Seller with regard to any other obligation owed to such Seller; and/or (iii) the Series F
Preferred held by such Seller. For purposes of any set-off against or cancellation of the Series F Preferred, (x) the number of
shares of Series F Preferred to be transferred to Purchaser or such Purchaser Indemnitee by the applicable Seller and cancelled
in satisfaction of such Loss, liability or other obligation shall be determined by dividing the aggregate amount of such Loss,
liability or other obligation by $1.95, as adjusted for any splits, equity dividends or similar transactions; and (y) the applicable
Sellers shall cooperate as requested to transfer the applicable portion of such securities to Purchaser or such other applicable
Purchaser Indemnitee for cancellation.

 

 

 

    	 	36	 

     

    

 

(b)       The
indemnification liability of any Seller under this Article VII shall be limited to an amount of funds equal to the number of shares
of Series F Preferred issued to such Seller at Closing multiplied by $1.95; provided, that, such limitation shall not apply
in the case of intentional breach, intentional misrepresentation or fraud.

 

Section 7.6.Treatment
of Indemnification Payments. All indemnification payments made under this Agreement shall be treated by the Parties as an adjustment
to the Transaction Consideration to the extent permitted by applicable Law.

 

Section 7.7.Right
to Indemnification Not Affected by Knowledge or Waiver. The right to indemnification, payment of Losses or other remedy based
upon breach of representations, warranties, covenants, agreements or obligations will not be affected by any investigation conducted
with respect to, or knowledge acquired (or capable of being acquired) at any time, whether before or after the Closing Date, with
respect to the accuracy or inaccuracy of or compliance with any such representation, warranty, covenant, agreement or obligation.
The waiver of any condition based on the accuracy of any representation or warranty, or on the performance of or compliance with
any covenant, agreement or obligation, will not affect the right to indemnification, payment of Losses or other remedy based on
such representations, warranties, covenants, agreements and obligations.

 

ARTICLE
VIII

TERMINATION

 

Section 8.1.Termination
of Agreement. Certain of the Parties may terminate this Agreement as provided below:

 

(a)       Purchaser,
Rennova and the Sellers may terminate this Agreement by mutual written consent at any time prior to the Closing;

 

(b)       Purchaser
or Rennova may terminate this Agreement (so long as Purchaser or Rennova is not in material breach of any of its representations,
warranties, covenants or agreements contained in this Agreement) by giving written notice to the Sellers at any time prior to the
Closing (i) in the event that any Seller or the Company has breached any representation, warranty, covenant or agreement contained
in this Agreement, which breach would cause the failure of any condition set forth in this Agreement and Purchaser or Rennova has
notified in writing the Sellers of the breach, and such breach has continued without cure for a period of ten (10) days after the
notice of breach, (ii) in the event that any Seller, or the Company has materially breached any covenant contained in this Agreement
and Purchaser or Rennova has notified in writing the Sellers of the breach, and such breach has continued without cure for a period
of ten (10) days after the notice of breach or (iii) if the Closing shall not have occurred on or before the Termination Date,
by reason of the failure of any condition precedent to have occurred;

 

 

 

    	 	37	 

     

    

 

(c)       In
the event that the transaction as proposed is not completed solely upon the decision of Genomas or its shareholders and Genomas
or its shareholders enter into another agreement with any other party within 12 months that leads to a Joint Venture of any kind
or the purchase and sale of Genomas in any form then Genomas will pay Rennova a penalty of $1,000,000; and

 

(d)       In
the event this Agreement is terminated, the Loan shall become due and payable as of the Termination Date. To secure the prompt
payment of the Loan, the Company grants to Rennova a continuing Lien upon all the assets of the Company whether now owned or existing
or hereafter created, acquired, or arising and wherever located including all proceeds thereof. The Company authorizes the filing
of such financing statements as are required to perfect the Lien.

 

ARTICLE
IX

MISCELLANEOUS

 

Section 9.1.Certain
Definitions.

 

(a)       For
purposes of this Agreement, the following terms shall have the meanings specified in this Agreement:

 

“Acquisition
Transaction” means any transaction involving: (i) the sale, license, disposition or acquisition of all or a substantial
portion of the assets of the Company; (ii) the issuance, disposition or acquisition of (A) any stock or other equity security of
the Company, (B) any option, call, warrant or right (whether or not immediately exercisable) to acquire any stock or other equity
security of the Company, or (C) any security, instrument or obligation that is or may become convertible into or exchangeable for
any stock or other equity security of the Company; or (iii) any merger, consolidation, share exchange, business combination, reorganization,
recapitalization or similar transaction involving the Company.

 

“Books and
Records” means all books and records of the Company, including files, manuals, price lists, mailing lists, distributor
lists, customer lists, sales and promotional materials, purchasing materials, documents evidencing intangible rights or obligations,
personnel records, accounting records and litigation files (regardless of the media in which stored).

 

“Business”
means the business of the Company as conducted or proposed to be conducted as of the date hereof, including all activities involving
the development, marketing and use of Phyzio Type Systems for DNA-guided management and prescription of drugs used to treat mental
illness, pain, heart disease and diabetes and pharmacogentic testing and consulting.

 

 

 

    	 	38	 

     

    

 

“Business
Day” means any day of the year on which national banking institutions in the City of New York are open to the public
for conducting business and are not required or authorized to close.

 

“Change of
Contract Payments” means any and all (i) bonuses or similar payments payable as a result of the transactions contemplated
hereby, and (iii) amounts payable to obtain any necessary consents or approvals.

 

“Code”
shall mean the Internal Revenue Code of 1986, as amended.

 

“Company Material
Adverse Change” or “Company Material Adverse Effect” means a Material Adverse Change or a Material
Adverse Effect with respect to the Company.

 

“Consent”
means any consent, approval, authorization, waiver, permit, grant, franchise, concession, agreement, license, exemption or order
of, registration, certificate, declaration or filing with, or report or notice to, any Person, including any Governmental Body.

 

“Contract”
means any contract, agreement, indenture, note, bond, loan, mortgage, license, instrument, lease, understanding, commitment or
other arrangement or agreement, whether written or oral.

 

“Documentation”
means printed, visual or electronic materials, reports, white papers, documentation, specifications, designs, flow charts, code
listings, instructions, user manuals, frequently asked questions, release notes, recall notices, error logs, diagnostic reports,
marketing materials, packaging, labeling, service manuals and other information describing the use, operation, installation, configuration,
features, functionality, pricing, marketing or correction of a product, whether or not provided to end users.

 

“Employment
Agreement” means an employment agreement in form and substance satisfactory to the Purchaser to be entered into by the
Company and Gualberto Ruaño on the Closing Date.

 

“GAAP”
means United States generally accepted accounting principles as in effect from time to time.

 

“Governing
Documents” means, with respect to any particular entity: (i) if a corporation, the articles or certificate of incorporation
and the bylaws; (ii) if a general partnership, the partnership agreement and any statement of partnership; (iii) if a limited partnership,
the limited partnership agreement and the certificate of limited partnership; (iv) if a limited liability company, the articles
of organization and operating agreement; (v) if another type of Person, any other charter or similar document adopted or filed
in connection with the creation, formation or organization of the Person; (vi) all equity holders’ agreements, voting agreements,
voting trust agreements, joint venture agreements, registration rights agreements or other agreements or documents relating to
the organization, management or operation of any Person or relating to the rights, duties and obligations of the equityholders
of any Person; and (vii) any amendment or supplement to any of the foregoing.

 

 

 

    	 	39	 

     

    

 

“Governmental
Body” means any government or governmental or regulatory authority or body thereof, or political subdivision thereof,
whether federal, state, local or foreign, or any agency, instrumentality or authority thereof, or any court or arbitrator (public
or private) or tribunal of competent jurisdiction.

 

“Indebtedness”
means, with respect to the Company at any applicable time of determination, without duplication: (i) all obligations for borrowed
money; (ii) all obligations evidenced by bonds, debentures, notes or other similar instruments or debt securities; (iii) all obligations
under swaps, hedges or similar instruments; (iv) all obligations in respect of letters of credit or bankers’ acceptances;
(v) all obligations, contingent or otherwise, arising from deferred compensation arrangements, severance or bonus plans or arrangements,
Employee Benefit Plans, employment agreements or similar arrangements payable as a result of the consummation of the transactions
contemplated hereby (regardless of whether any additional event, in addition to the consummation of the transactions contemplated
hereby, is required to give rise to such obligations); (vi) all obligations secured by a Lien; (vii) all guaranties in connection
with any of the foregoing; (viii) all obligations recorded or required to be recorded as capital leases in accordance with GAAP
as of the date of determination of such Indebtedness; (ix) all obligations for the deferred purchase price of property or services
or the acquisition of a business or portion thereof, whether contingent or otherwise, as obligor or otherwise, at the maximum amount
payable in respect thereof, regardless of whether such amount is contingent on future performance; (x) all obligations created
or arising under any conditional sale or other title retention agreement with respect to acquired property; (xi) all deferred rent
obligations; (xii) all obligations arising from cash or book overdrafts; (xiii) all liabilities classified as non-current liabilities
in accordance with GAAP as of the date of determination of such Indebtedness (other than any “deferred revenue” incurred
in the ordinary course of business); (xiv) all checks in transit; and (xv) all accrued interest, prepayment premiums, fees, penalties,
expenses or other amounts payable in respect of any of the foregoing.

 

“Intellectual
Property” means: (i) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all
improvements thereto, and all patents, patent applications, and patent disclosures, together with all reissuances, continuations,
continuations-in-part, revisions, extensions, and reexaminations thereof; (ii) all trademarks, service marks, trade dress, logos,
trade names, and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including
all goodwill associated therewith, and all applications, registrations and renewals in connection therewith; (iii) all copyrightable
works, all copyrights, and all applications, registrations and renewals in connection therewith; (iv) all trade secrets and confidential
information (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes
and techniques, technical data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and
business and marketing plans and proposals); (v) all computer software (including data and related documentation); (vi) all other
proprietary rights; and (vii) all copies and tangible embodiments thereof (in whatever form or medium).

 

“Internal
Systems” means the Software and Documentation and the computer, communications and network systems (both desktop and
enterprise-wide), equipment, materials and test apparatus used by the Company in the Business or to develop, manufacture, assemble,
provide, distribute, support, maintain or test the Customer Offerings, whether located on the premises of the Company or hosted
at a third party site.

 

 

 

    	 	40	 

     

    

 

“IRS”
means the United States Internal Revenue Service.

 

“Knowledge”
or words of similar effect, regardless of case, means, with respect to Sellers, the knowledge of (i) each Seller, and (ii) each
officer and director of the Company. Each of the foregoing Persons will be deemed to have knowledge of a particular fact or other
matter if: (A) such Person is actually aware of such fact or matter; (B) a prudent individual could be expected to discover or
otherwise become aware of such fact or matter after due inquiry, or (C) a similarly situated Person could reasonably be expected
to have knowledge of such fact or matter.

 

“Law”
means any federal, state, local or foreign law (including common law), statute, code, ordinance, rule, regulation or other requirement
or rule of law of any Governmental Body.

 

“Legal Proceeding”
means any judicial, administrative or arbitral actions, suits, proceedings (public or private), claims, hearings, investigations,
charges, complaints, demands or governmental proceedings.

 

“Liability”
means any liability, obligation or commitment of any nature whatsoever (whether known or unknown, asserted or unasserted, absolute
or contingent, accrued or unaccrued, liquidated or unliquidated, matured or unmatured, or due or to become due, or otherwise),
including any liability for Taxes.

 

“Lien”
means any lien (including any Tax lien), pledge, mortgage, deed of trust, security interest, claim, demand, lease, charge, option,
warrant, call, right of first refusal, easement, servitude, transfer restriction or any other encumbrance, restriction or limitation
whatsoever.

 

“Material
Adverse Effect” or “Material Adverse Change” with respect to a Person means any event, occurrence,
fact, condition, change or effect that is, or could reasonably be expected to become, individually or in the aggregate, materially
adverse to the business, properties, results of operations, prospects or condition (financial or otherwise) of such Person or to
the ability of such Person to consummate timely the transactions contemplated hereby other than changes in the following: (i) general
market, economic or political conditions; (ii) GAAP or statutory accounting principles; and (iii) acts of terrorism or war (whether
or not declared), except, in each case, to the extent such changes cause a disproportionate and negative effect on or change to
such Person as compared to the industry in which such Person operate as a whole.

 

“Order”
means any order, injunction, judgment, decree, ruling, writ, assessment or arbitration award.

 

“Permit”
means any approval, consent, license, certificate, accreditation, permit, waiver, or other authorization issued, granted, given,
or otherwise made available by or under the authority of any Governmental Body or pursuant to Law.

 

“Permitted
Liens” means (i) liens for real estate Taxes not yet due and payable or being contested in good faith by appropriate
procedures as disclosed herein and for which there are adequate accruals or reserves on the Balance Sheet, and (ii) liens arising
under equipment leases with third parties which were entered into in the ordinary course of business consistent with past practices
which are not, individually or in the aggregate, material to the Business or the assets of the Company.

 

 

 

    	 	41	 

     

    

 

“Person”
means any individual, corporation, partnership, firm, joint venture, association, joint-stock company, trust, unincorporated organization,
Governmental Body or other entity.

 

“Proprietary
Software Products” means all versions (whether or not released) of the object code, source code and scripts and any software
or firmware, prebuilt solutions, or scripts conceived, created, reduced to practice, developed or under development by or on behalf
of the Company, together with all Documentation related thereto.

 

“Release”
means any actual or threatened release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal,
migration or leaching into the indoor or outdoor environment, or into or out of any property.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Seller Transaction
Expenses” means any and all legal, accounting, consulting, investment advisory, brokers and other fees, costs and expenses
of Sellers or the Company relating to the transaction contemplated hereby.

 

“Software”
means computer software code, applications, utilities, development tools, diagnostics, databases and embedded systems, whether
in source code, interpreted code and/or object code form.

 

“Subsidiary”
means, with respect to any Person, any corporation, partnership, association, trust or other form of legal entity of which (i)
more than fifty percent (50%) of the voting power of the outstanding voting securities are directly or indirectly owned by such
Person or (ii) such Person or any Subsidiary of such Person is a general partner (excluding partnerships in which such party or
any Subsidiary of such Person does not have a majority of the voting interests in such partnership).

 

“Tax”
or “Taxes” means any federal, state, provincial, local or foreign income, alternative minimum, accumulated earnings,
personal holding company, franchise, capital stock, net worth, capital, profits, windfall profits, gross receipts, value added,
sales, use, goods and services, excise, customs duties, transfer, conveyance, mortgage, registration, stamp, documentary, recording,
premium, severance, environmental (including taxes under Section 59A of the Code or any analogous or similar provision of any state,
local or foreign Law or regulation), real property, personal property, ad valorem, intangibles, unclaimed property, rent, occupancy,
license, occupational, employment, unemployment insurance, social security, disability, workers’ compensation, payroll, health
care, escheat, unclaimed property, withholding, estimated or other similar tax, duty or other governmental charge or assessment
or deficiencies thereof, and including any interest, penalties or additions to tax attributable to the foregoing. The terms “Tax”
and “Taxes” also include obligations to pay Taxes of any other Person, pursuant to any contract, law, regulation or
otherwise.

 

 

 

    	 	42	 

     

    

 

“Tax Return”
means any return, report, declaration, form, claim for refund or information return or statement relating to Taxes, including any
schedule or attachment thereto, and including any amendment thereof.

 

“Transaction
Documents” means, with respect to any Person, this Agreement together with any other agreements, instruments, certificates
and documents executed by such Person in connection herewith or therewith or in connection with the transactions contemplated hereby
or thereby.

 

“Treasury
Regulations” means the regulations promulgated under the Code, including temporary and proposed regulations.

 

“WARN”
means the Worker Adjustment and Retraining Notification Act, as amended.

 

Section 9.2.Expenses.
Except as otherwise provided in this Agreement, each of the Parties shall bear its own fees, costs and expenses (including legal,
accounting, consulting and investment advisory fees and expenses) incurred in connection with this Agreement and the transactions
contemplated hereby.

 

Section 9.3.Governing
Law; Jurisdiction; Venue. This Agreement shall be governed by and construed in accordance with the internal laws of the state
of Florida without giving effect to any choice or conflict of law provision or rule (whether of the state of Florida or any other
jurisdiction) that would cause the application of the laws of any jurisdiction other than the state of Florida. Each of the Parties
submits to the exclusive jurisdiction of any state or federal court within Palm Beach County in the state of Florida in any action
or proceeding arising out of or relating to this Agreement and agrees that all claims in respect of the action or proceeding shall
be exclusively heard and determined in any such court. The Parties hereby irrevocably waive, to the fullest extent permitted by
applicable Law, any objection which they may now or hereafter have to the laying of venue of any such dispute brought in such court.
Each of the Parties waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought.

 

Section 9.4.Entire
Agreement; Amendments and Waivers. This Agreement (including the schedules and exhibits hereto) represents the entire understanding
and agreement among the Parties with respect to the subject matter hereof and can be amended, supplemented or changed, and any
provision hereof can be waived, only by written instrument making specific reference to this Agreement signed by Purchaser or Rennova,
in the case of an amendment, supplement, modification or waiver sought to be enforced against Purchaser or Rennova, or the Sellers,
in the case of an amendment, supplement, modification or waiver sought to be enforced against Sellers. The waiver by any Party
of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach
or as a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and no delay in exercising,
any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right,
power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.
All remedies hereunder are cumulative and are not exclusive of any other remedies provided by Law.

 

 

 

    	 	43	 

     

    

 

Section 9.5.Section
Headings. The section headings of this Agreement are for reference purposes only and are to be given no effect in the construction
or interpretation of this Agreement.

 

Section 9.6.Notices.
All notices and other communications under this Agreement shall be in writing and shall be given by personal delivery, nationally
recognized overnight courier or certified mail at the following addresses (or to such other address as a Party may have specified
by notice given to the other Party pursuant to this provision):

 

	If to the Company or the Sellers:	 	
        Gualberto Ruano, M.D., Ph.D.

        67 Jefferson Street

        Hartford, Connecticut 06106

	 	 	 
	If to Purchaser or Rennova, to:	 	
        Victoria Nemerson, Esq.

        General Counsel

        Medytox Solutions, Inc.

        400 S. Australian Avenue

        West Palm Beach, Florida 33401

	 	 	 
	With a copy (which shall not constitute notice) to:	 	
        J. Thomas Cookson, Esq.

        Akerman LLP

        Three Brickell City Centre

        98 Southeast Seventh Street

        Miami, Florida 33131

 

Any such notice or
communication shall be deemed to have been received (i) when delivered, if personally delivered, (ii) on the next Business Day
after dispatch, if sent postage pre-paid by nationally recognized, overnight courier guaranteeing next Business Day delivery, and
(iii) on the fifth (5th) Business Day following the date on which the piece of mail containing such communication is posted, if
sent by certified mail, postage prepaid, return receipt requested.

 

Section 9.7.Severability.
If any provision of this Agreement is invalid, illegal or unenforceable, the balance of this Agreement shall remain in effect.
The Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely
as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the greatest extent possible.

 

Section 9.8.Binding
Effect; Assignment; Third-Party Beneficiaries. This Agreement shall be binding upon and shall inure to the benefit of the Parties
and their respective successors and permitted assigns; provided, however, that no Party may assign its rights and/or obligations
hereunder without the consent of the other Parties. Notwithstanding the foregoing, Purchaser may assign its rights and obligations
pursuant to this Agreement, in whole or in part, in connection with any disposition or transfer of all or any portion of Purchaser,
the Company or their respective businesses in any form of transaction without the consent of any of the other Parties. In addition,
Purchaser may assign any or all of its rights pursuant to this Agreement to any lender to Purchaser, Rennova or the Company as
collateral security without the consent of any of the other Parties. No assignment by Purchaser, without the consent of the other
Parties, shall relieve the Purchaser of any of its obligations under this Agreement. Except as provided in this Agreement with
respect to Persons entitled to indemnification thereunder, nothing in this Agreement shall create or be deemed to create any third
party beneficiary rights in any Person.

 

 

 

    	 	44	 

     

    

 

Section 9.9.Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together
will constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile,
portable document format or other electronic means shall be effective as delivery of a manually executed counterpart to this Agreement.

 

Section 9.10.Remedies
Cumulative. Except as otherwise provided herein, no remedy herein conferred upon a Party hereto is intended to be exclusive
of any other remedy. No single or partial exercise by a Party hereto of any right, power or remedy hereunder shall preclude any
other or further exercise thereof. Purchaser, Rennova or any of their Affiliates may, at their election, set-off against any amounts
due to any Seller or any of their respective Affiliates, any Losses or other amounts for which such Seller (or any Affiliate thereof)
may be responsible to pay to Purchaser, Rennova or any of their Affiliates.

 

Section 9.11.Schedules.
The schedules referred to herein are attached hereto and incorporated herein by this reference. The schedules delivered by Sellers
to Purchaser and Rennova in connection with the execution of this Agreement shall be arranged to correspond to the specific sections
and subsections of this Agreement. If any Party hereto has breached any representation, warranty, or covenant contained herein
in any respect, the fact that there exists another representation, warranty, or covenant relating to the same subject matter (regardless
of the relative levels of specificity) which the Party has not breached will not detract from or mitigate the fact that the Party
is in breach of the first representation, warranty or covenant.

 

Section 9.12.Interpretation.
When a reference is made in this Agreement to an article, section, paragraph, clause, schedule, such reference shall be deemed
to be to this Agreement unless otherwise indicated. The text of all schedules is incorporated herein by reference. Whenever the
words “include,” “includes” or “including” are used in this Agreement, they shall be deemed
to be followed by the words “without limitation.” As used herein, words in the singular will be held to include the
plural and vice versa (unless the context otherwise requires), words of one gender shall be held to include the other gender (or
the neuter) as the context requires, and the terms “hereof”, “herein”, and “herewith” and words
of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision
of this Agreement.

 

Section 9.13.Arm’s
Length Negotiations. Each Party herein expressly represents and warrants to all other Parties hereto that (a) said Party has
had the opportunity to seek and has obtained the advice of its own legal, tax and business advisors before executing this Agreement;
and (b) this Agreement is the result of arm’s length negotiations conducted by and among the Parties and their respective
counsel.

 

Section 9.14.Construction.
The Parties agree and acknowledge that they have jointly participated in the negotiation and drafting of this Agreement. In the
event of an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by
the Parties and no presumptions or burdens of proof shall arise favoring any Party by virtue of the authorship of any of the provisions
of this Agreement. Any reference to any federal, state, local, or foreign statute or Law shall be deemed also to refer to all rules
and regulations promulgated thereunder, unless the context requires otherwise.

 

 

 

    	 	45	 

     

    

 

Section 9.15.Specific
Performance. The Parties agree that irreparable damage would occur if any provision of this Agreement were not performed by
Sellers in accordance with the specific terms hereof or were otherwise breached by Sellers. It is accordingly agreed that Purchaser
shall be entitled, without posting a bond or similar indemnity, to an injunction or other equitable relief to prevent breaches
of this Agreement or to enforce specifically the performance of the terms. Each Seller agrees that he or it will not oppose the
granting of an injunction, specific performance and other equitable relief when expressly available pursuant to the terms of this
Agreement on the basis that Purchaser has an adequate remedy at law or an award of specific performance is not an appropriate remedy
for any reason at law or equity. Notwithstanding anything to the contrary in this Agreement, the Parties agree that the Company
and Sellers shall not be entitled to an injunction, specific performance or other equitable relief to prevent breaches of this
Agreement or to enforce specifically the terms hereof.

 

Section 9.16.Waiver
of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

Section 9.17.Time
of Essence. With regard to all dates and time periods set forth or referred to in this Agreement, time is of the essence.

 

 

 

 

 

 

    	 	46	 

     

    

 

 

IN WITNESS WHEREOF, this
Stock Purchase Agreement has been executed by or on behalf of each of the Parties as of the day first written above.

 

 

	 	
        PURCHASER:

         

        MEDYTOX DIAGNOSTICS, INC.

        

        

        By: /s/ Seamus Lagan

        Name: Seamus Lagan

        Title: Chief Executive Officer

         

	 	 
	 	
        RENNOVA:

         

        RENNOVA HEALTH, INC.

        

        

        By: /s/ Seamus Lagan

        Name: Seamus Lagan

Title: Chief Executive Officer and President

         

	 	 
	 	
        COMPANY:

         

        GENOMAS, INC.

        

        

        By: /s/ Gualberto Ruaño, M.D.

        Name: Gualberto Ruaño, M.D

        Title: President and CEO

         

	 	 
	 	
        SELLERS:

         

        PHENOMAS LLC

         

         

        By: /s/ Gualberto Ruaño, M.D.

        Name: Gualberto Ruaño, M.D

        Title: Manager

         

        /s/ Robert Patricelli

        Robert Patricelli

         

 

    	 	47	 

     

    

 

 

 

	 	
        LES INVESTMENTS LLC

         

         

        By: /s/ David M. Roth

        Name: David M. Roth

        Title: Manager

         

        /s/ William Popik

        William Popik, M.D.

         

	 	 
	 	
        THE ROGOSIN INSTITUTE

         

         

        By: /s/ Bruce Gordon

        Name: Bruce Gordon

        Title: Chief Operating Officer

         

        /s/ Henry Zachs

        Henry Zachs

         

        /s/ Gualberto Ruaño, M.D

        Gualberto Ruaño, M.D.

         

        /s/ Andreas Windemuth

        Andreas Windemuth

         

	 	 

 

 

 

    	 	48	 

     

    

 

SCHEDULE A

Creditor & Lender Report

	Creditor and Lender Report as of 7/31/2016	 	 	 	 
	 	 	 	 	 	 
	Accounts Payable	 	 	 	 	 
	Arbot Software	8,880.00	 	 	 	 
	Cantor Colburn LLP	2,000.00	 	 	 	 
	Wiggin Dana LLP	37,996.80	 	 	 	 
	Technology Park	45,000.00	 	 	 	 
	Genmark Diagnostics	8,224.00	 	 	 	 
	Hartford Hospital Rent	16,265.70	 	 	 	 
	Phenomas LLC	200,000.00	 	 	 	 
	C-3 Ventures LLC	20,000.00	 	 	 	 
	Total Accounts Payable	338,366.50	 	 	 	 
	 	 	 	 	 	 
	Other Current Liabilities (1)	 	 	 	 	 
	AMEX-Blue Credit Card	37,778.00	 	 	 	 
	BOA Credit Card	25,031.00	 	 	 	 
	UBS Credit Card	20,770.00	 	 	 	 
	Deferred RNVA Revenue	255,800.00	 	 	 	 
	Closing Costs (Est.)	50,000.00	 	 	 	 
	Wells Fargo LOC	96,110.00	 	 	 	 
	Total Other Liabilities	485,489.00	 	 	 	 
	 	 	 	 	 	 
	Total Current Liability + Payables	823,855.50	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Loans	 	 	 	 	 
	Loan - Web Bank (factoring) (2)	176,847.00	 	 	 	 
	Notes Payable - CT DECD 2012 (3)	134,118.00	 	 	 	 
	 	 	 	 	 	 
	Total Loans	310,965.00	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	Notes	 	 	 	 	 
	(1) There is a disputed payable with Hartford Hospital for a research	 
	contract: $94,337.43.  Settlement at an amount below is anticipated.	 
	(2) Payable over an estimated 2.4 year period at $426.14 per workday.	 
	(3) Payable over a period of 69 months at $2,105.20 per month.	 	 	 
	 	 	 	 	 	 

 

 

    	 	Schedule A-1	 

     

    

 

SCHEDULE B(i)

Financial Statements

Condensed Balance Sheet for 7-Month
Period 1/1/16 – 7/31/16

	Genomas, Inc.
	Condensed Balance Sheet
	UNAUDITED
	 	Jul, 31	 	Dec, 31
	 	2016	 	2015
	ASSETS	 	 	 
	Cash 	29,170 	 	140,556 
	Accounts receivable	68,969 	 	217,444 
	Lab supplies	16,380 	 	26,380 
	   Total Current Assets	114,519 	 	384,380 
	Net Fixed Assets	21,415 	 	21,502 
	Deferred Patent/Trademark Expense	201,704 	 	206,825 
	TOTAL ASSETS	337,638 	 	612,707 
	 	 	 	 
	Accounts Payable	324,672 	 	420,831 
	Accrued Legal Fees	37,997 	 	38,012 
	Accrued Payroll	    6,846 	 	   2,774 
	Accrued Operating Expense	  95,745 	 	      161,990 
	Deferred Revenue	  20,000 	 	        20,000 
	Business Line of Credit	  96,124 	 	        96,997 
	Loan – Factoring	    176,847 	 	     - 
	LOC - Business Partner	    255,800 	 	      100,000 
	Notes Payable (Includes Accrued Interest)	1,471,630 	 	1,454,317 
	      Total Current Liabilities	2,485,661 	 	2,294,921 
	Long-term Liabilities:	 	 	 
	    DECD Equipment Financing	      -   	 	60,125 
	    DECD Express Loan	134,118 	 	148,217 
	   Total Liabilities	2,619,779 	 	2,503,263 
	   Equity	 	 	 
	      Retained Earnings	(7,100,979)	 	(6,621,904)
	      Shareholders’ Equity	5,210,423 	 	5,210,423 
	      Net Income	(391,585)	 	(479,075)
	   Total Equity	(2,282,141)	 	(1,890,556)
	TOTAL LIABILITIES AND EQUITY	337,638 	 	612,707 

 

 

 

    	 	Schedule B-1	 

     

    

SCHEDULE B(ii)

Financial Statements

 

	Genomas, Inc.
	Condensed Income Statement
	UNAUDITED 
	 	7 months ended	 
	 	7/31/16	7/31/15	 
	Revenues:	 	 	 
	 Total Revenue	147,343 	714,516 	 
	 Total COGS & Selling Exp.	(346,812)	(141,949)	 
	    LPH PhyzioType Revenues	97,074 	617,066 	 
	    Cost of Goods Sold	(271,223)	(507,527)	 
	         Gross Margin	(174,149)	109,539 	 
	         % of Revenue	-179.4%	17.8%	 
	    Sales & Marketing	37,773 	170,186 	 
	         LPH Profit Contribution	(211,922)	(60,647)	 
	   Grants & Contracts Revenue	50,269 	97,450 	 
	   Grants & Contracts Exp.	(37,816)	(89,549)	 
	        G&C Profit Contribution	12,453 	7,901 	 
	Expenses:	 	 	 
	  Admin. & General	141,822 	179,777 	 
	Total Operating Expense	141,822 	179,777 	 
	EBITDA	(341,291)	(232,523)	 
	  Depreciation & Amortization	5,208 	5,243 	 
	EBIT	(346,499)	(237,766)	 
	 Other Income	50,000 	 	 
	 Other Expenses	(95,086)	(81,168)	 
	Pretax Income	(391,585)	(318,934)	 
	  Income Taxes	 	 	 
	Net Income	(391,585)	(318,934)	 

 

 

 

    	 	Schedule B-2	 

     

    

SCHEDULE B(iii)

Financial Statements 

 

	Genomas, Inc.
	Condensed Statement of Cash Flows
	UNAUDITED
	 	7 Mo. To	 
	OPERATING ACTIVITIES	7/31/16	 
	Net Income	(391,585)	 
	Adjustments to Reconcile Net Income to Net Cash:	 	 
	      Depreciation and Amortization	5,208 	 
	Changes in Assets and Liabilities:	 	 
	      Accounts Receivable	      148,475 	 
	      Prepaid Lab Supplies	        10,000 	 
	      Accounts Payable	       (96,159)	 
	      Accrued Expense	  (44,875.00)	 
	      Deferred Revenue	           -   	 
	Net cash provided by operating activities	(368,936)	 
	INVESTING ACTIVITIES	 	 
	      Purchases of Property & Equipment	                -   	 
	Net cash provided by investing activities	                -   	 
	FINANCING ACTIVITIES	 	 
	      LOC Wells Fargo	(873)	 
	      LOC - Business Partner	155,800 	 
	      Loan Factoring	176,847 	 
	      DECD Equipment Financing	(60,125)	 
	      DECD Express Loan	(14,099)	 
	Net cash provided by financing activities	257,550 	 
	Net cash increase for period	(111,386)	 
	Cash at Beginning of Period	140,556 	 
	Cash at end of period	29,170 	 

 

 

 

 

    	 	Schedule B-3	 

     

    

 

SCHEDULE C

Accounts Receivable and Notes Receivable

 

 

 

 

 

 

 

 

 

 

 

 

    	 	Schedule C-1	 

     

    

 

 

SCHEDULE D

Sellers and Shares

	Sellers:	Resident of:
	Phenomas LLC	Connecticut
	Robert Patricelli	Connecticut
	LES Investments LLC	Florida
	William Popik, M.D.	Connecticut
	The Rogosin Institute	New York
	Henry Zachs	Connecticut
	Gualberto Ruaño, M.D.	Connecticut
	Andreas Windemuth	Massachusetts

 

	Genomas, Inc.
	Fully Diluted Shares Outstanding as of September ___, 2016   CONFIDENTIAL
	 	 	 	 	 	 
	 	Shares Outstanding
	 	 	Series and Price per Share	 
	 	 	$1.00 	$1.45 	$1.59 	 
	 	 	Series A 	Series B	Series C	 
	Shareholder 	Common 	Preferred	Preferred	Preferred	Total
	Name	Shares	 Shares (1)	 Shares (1) 	Shares (1)	 
	Preferred	 	 	 	 	 
	Phenomas LLC (2)	 	349,999 	 	1,572,327 	1,922,326 
	Rennova Health (3)	 	500,001 	345,000 	 	845,001 
	Robert Patricelli	 	350,000 	 	 	350,000 
	LES Investments LLC (4)	 	350,000 	68,965 	 	418,965 
	William Popik, M.D.	 	 	137,931 	 	137,931 
	The Rogosin Institute	 	 	68,965 	 	68,965 
	Henry Zachs	 	 	68,965 	 	68,965 
	Common	 	 	 	 	 
	Gualberto Ruaño, M.D.	1,742,300 	 	 	 	1,742,300 
	Phenomas LLC (2)	69,242 	 	 	 	69,242 
	Andreas Windemuth	128,208 	 	 	 	128,208 
	Totals (5, 6)	1,939,750 	1,550,000 	689,826 	1,572,327 	5,751,903 
	 	 	 	 	 	 
	Notes	 	 	 	 	 
	(1) Common Equivalents  	 	 	 	 	 
	(2) Dr. Gualberto Ruaño is Manager of Phenomas LLC	 	 	 
	(3) Rennova Health acquired Series A + B shares formerly held by Hartford Healthcare	 
	(4) Mr. David Roth is Manager of LES Investments LLC	 	 	 
	(5) Total Preferred Shares, Series A+B+C = 3,812,153	 	 	 
	(6) Series A+B shares = 2,239,826	 	 	 	 	 

 

 

 

 

    	 	Schedule D-1	 

     

    

 

SCHEDULE E

Shares

	Name of Seller	Number of RNVA Shares of Series F Preferred to be Issued
	Gualberto Ruano, M.D.	12,115
	Phenomas LLC	1,525,897
	Robert Patricelli 	62,562
	LES Investments LLC	77,113
	William Popik, M.D. 	33,066
	The Rogosin Institute 	16,417
	Henry Zachs 	16,417
	Andreas Windemuth, Ph.D.	6,410

 

NOTE:

For the avoidance of doubt, the maximum
number of common shares that can be received upon conversion of 100% of the above shares of Series F Preferred is 897,436.

 

 

 

    	 	Schedule E-1	 

     

    

 

 

SCHEDULE F

Cash Requirement Schedule

 

 

 

 

    	 	Schedule F-1	 

     

    

 

SCHEDULE G

Genomas Intellectual Property

U.S. Patents

		·	U.S. Patent 7,747,392: Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients;
Gualberto Ruaño, Andreas Windemuth, inventors

 

		·	U.S. Patent 8,012,718: Physiogenomic Method for Predicting Psychotropic Induced Diabetes and Metabolic
Syndromes I; Gualberto Ruaño, Andreas Windemuth, John W. Goethe, inventors

 

		·	U.S. Patent 8,389,247: Physiogenomic Method for Predicting Psychotropic Induced Diabetes and Metabolic
Syndromes II; Gualberto Ruaño, Andreas Windemuth, John W. Goethe, inventors

		·	U.S. Patent 8,476,012: Physiogenomic Method for Predicting Metabolic and Cardiovascular Side Effects
of Thiazolidinediones; Gualberto Ruaño, Andreas Windemuth, Steven D. Hanks, inventors

 

U.S. Patent Applications

		·	Publication US 2007/0196841: Physiogenomic Method for Predicting Response to Diet; Gualberto
Ruaño, Andreas Windemuth, Jeff S. Volek, inventors

 

		·	Publication US 2007/0202518: Physiogenomic Method for Predicting Statin Injury to Muscle and
Muscle Side Effects; Gualberto Ruaño, Alan Wu, Paul D. Thompson, inventors

 

		·	Publication US 2008/0070247: Physiogenomic Method for Predicting Effects of Exercise; Gualberto
Ruaño, Andreas Windemuth, Paul D. Thompson, inventors

 

		·	Publication US 2011/0098186: Physiogenomic Method for Predicting Antidepressant and Anxiolytic
Drug Metabolic Risk; Gualberto Ruaño, David V. Villagra, Mohan Kocherla, Andreas Windemuth, John W. Goethe, inventors

 

Copyright

		·	U.S. Copyright Registration Number VA 1-797-692: Personalized Health Portal; Gualberto Ruaño,
author

 

Trademarks

		·	U.S. Trademark Registration Number 3155560: Genomas G logo; Gualberto Ruaño, author

 

		·	U.S. Trademark Registration Number 3155607: Genomas; Gualberto Ruaño, author

 

		·	U.S. Trademark Registration
Number 3877338: PhyzioType; Gualberto Ruaño

 

 

 

    	 	Schedule G-1	 

     

    

 

SCHEDULE H

Leased Property

 

The current lease held by Genomas, Inc., is
by and among Genomas, Inc., and Hartford HealthCare Corporation with the demised premises being 2,565 square feet in what is known
as The East Building located at 67 Jefferson Street, Hartford, Connecticut, 06106. Existing lease shall terminate upon the closing
of this Agreement.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	Schedule H-1	 

     

    

 

SCHEDULE I

NIH Funding

 

	Grant #	Grant Name	Dates	Total Awarded
	R43 MH73291-01	Gene Markers: Antipsychotic Induced Metabolic Syndrome	2/01/2005-9/30/2005	$107,000.00
	R43 MH73291-02	DNA Diagnostics for Minimizing Metabolic Side Effects of Antipsychotics 	8/01/2007-7/31/2010	$1,507,600.00
	R44 GM085201-01	DNA Diagnostic System for Statin Safety and Efficacy	1/01/2008-6/30/2008	$139,300.00
	R44 GM085201-02	DNA Diagnostic System for Statin Safety and Efficacy	7/01/2008-6/30/2010	$1,384,200.00
	R44 GM085201-03	System for DNA-Guided Personalization of Statin Therapy	5/01/2011-4/30/2014	$1,439,300.00
	R43 MH075481-01	Physiogenomic Arrays for Clinical Neuropsychiatry	9/01/2005-8/31/2007	$400,000.00
	R43 MH075481-03A2	MRI DNA Biomarkers for Neuropsychiatric Disease	9/02/2009 -8/31/2013	$1,349,950.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	Schedule I-1	 

     

    

 

SCHEDULE J

Insurance Coverage 

 

	Policy	Effective Dates	Carrier	Insured	Change in Control
	 	 	 	 	 
	Professional Liability 	10.18.2015 - 10.18.2016	Evanston	
        Genomas, Inc.

        Gualberto Ruano, MD
	
        Post-closing -we have 30 days to notify the carrier
        of the sale and our intent with the policy.

        Will the acquiring company provide coverage?

	BOP	7.9.2015 - 7.9.16	The Hartford	Genomas, Inc.	
        Post-closing, we will notify the carrier of coverage
        status.

        Will the acquiring company provide coverage?

	D&O	6.1.2015 – 7.25.16	National Casualty	Genomas, Inc.	Carrier is aware of closing and extended the policy. Post-closing there is no coverage. We will have 30 days to purchase tail for prior acts.
	WC	9.2.2012 – 9.12.2016	The Hartford	Genomas, Inc.	
        Post-closing, we will have to notify carrier of
        transaction. The WC will need to be under the tax ID of where EE’s are being paid.

        Will the acquiring company provide coverage?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	Schedule J-1	 

     

    

 

SCHEDULE K

Brokerage Agreement

 

www.technologypark.com

220 Davidson Avenue, Somerset, NJ 08873

Tel: +1-732-390-7435; Fax: +1-718-304-1177

Email: contact@technologypark.com

 

 

June 28, 2016

 

Gualberto Ruaño, M.D., Ph.D.

Genomas, Inc.

67 Jefferson Street

Hartford, CT 06106

 

Dear Dr. Ruaño:

 

As per our phone conversation today, I am writing
this to confirm that we will accept $45,000 as our total advisory fees for helping Genomas find a buyer. This fee will be payable
at closing when Genomas completes its sale transaction with Rennova Health, Inc.

 

Payment of this $45,000 will free Genomas from
any future financial obligations to TechnologyPark.com.

 

We wish Genomas and Rennova all the best in
the future.

Best regards,

 

Yatin B. Thakore, Ph. D., CBI

Managing Partner

TechnologyPark.com

 

 

 

 

    	 	Schedule K-1	 

     

    

 

SCHEDULE L

Licenses & Permits

 

Credentials of Genomas

 

The Laboratory of Personalized Health (LPH) is
a Division of Genomas, Inc. Genomas is a biomedical company advancing DNA-Guided medicine with revolutionary PhyzioTypeTM
systems for personalized health.

 

The LPH is a fully certified and licensed high-complexity
DNA testing center and clinical laboratory.

 

Certified:

Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services.

CLIA (Clinical Laboratory Improvement Amendments) Laboratory Certificate

CLIA ID # 07D1036625

Expiration Date: July 10, 2017

National Provider Identifier (NPI) # 1336325497

 

Licensed:

Connecticut Department of Public Health

License # CL-0644

Expiration Date: June 30, 2017

New York Department of Health

Permanent Facility Identifier 8648

Expiration Date: June 30, 2017

California Department of Public Health

Lab ID # COS 00800405

Expiration Date: January 31, 2017

Florida Agency for Health Care Administration

License # 800027771

Expiration Date: August 10, 2017

Rhode Island Department of Health

License # LCO-0059

Expiration Date: December 31, 2017

 

 

 

    	 	Schedule L-1	 

     

    

 

Schedule M

List of Existing Contracts and Agreements

Genomas Inc. (August 31, 2016)

 

		1.	Employment contracts

		a.	Gualberto Ruaño, M.D., Ph.D.

		b.	Mohan Kocherla

		c.	Kelly Santana

		d.	James Graydon

		e.	Michael Acosta

 

		2.	Contracts with independent contractors

		a.	Professional Services Agreement with Robert Scherrer

		b.	Consulting Service Agreement with Arbot Software LLC

		c.	Service Contract with Comprehensive Business Solutions

		d.	Consulting Agreement with Conatus Consulting LLC

 

		3.	Grant Awards and Contracts

		a.	Consortium Award for Agency for Health Research & Quality (AHRQ) grant to Hartford Hospital

		b.	Grant award from Hartford Hospital Auxiliary for MEDtuning cards in Primary Care clinic

 

		4.	Services to State agencies

		a.	Payments from Invoices to  CT Department of Mental Health and Addiction Services (DMHAS)

 

		5.	Contracts with Distributors

		a.	Distributor Agreement with Empire Island Corporation

		b.	Distributor Agreement with Healthy Chemist Corporation

		c.	Reference Laboratory Service Agreement with GENETWORx LLC

		d.	Distributor Agreement with MediPro Direct Inc.

 

		6.	Contracts with Laboratories

		a.	Laboratory Service Agreement with Clinical laboratory Partners

		b.	Laboratory Service Agreement with HRP (Hato Rey Pathology) Labs

		c.	Laboratory Service Agreement with Medytox Diagnostics Inc.

		d.	Contract Research and License Agreement with AutoGenomics Inc.

		e.	Laboratory Subcontractor Services Agreement with PersonalizeDX Labs division, AutoGenomics

 

		7.	Contracts with Lenders

		a.	American Express Blue credit card, Account # 3723 238020 11003

		b.	Bank of America credit card, Account # 4339 9318 0109 0200

		c.	Web Bank loan, Agreement # MBP 8495397, Account ID: 307075

		d.	Wells Fargo line of credit, Account # 5474 6488 0531 3915

		e.	Connecticut Dept. of Economic and Community Development (DECD), Loan # 20120642000012

 

 

    	 	Schedule M-1	 

     

    

 

SCHEDULE N

Bank Accounts; Powers of Attorney

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	Schedule N-1	 

     

    

 

 

 

Schedule O

 

CERTIFICATE OF DESIGNATION

of

SERIES F CONVERTIBLE PREFERRED STOCK

of

RENNOVA HEALTH, INC.

(Pursuant to Section 151(g) of the

Delaware General Corporation Law)

 

Rennova Health, Inc.,
a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies
that the following resolution was duly adopted by the Board of Directors of the Corporation on ____________, 2016 pursuant to Section
151(g) of the Delaware General Corporation Law:

 

RESOLVED, that
pursuant to the authority vested in the Board of Directors (the “Board”) of Rennova Health, Inc. (the “Corporation”)
by the Corporation’s Certificate of Incorporation, and in accordance with the Delaware General Corporation Law (the “DGCL”),
Section 151, the Board hereby designates the terms of the Series F Convertible Preferred Stock of the Corporation and hereby states
the number of shares, and fixes the powers, designations, preferences and relative, participating, optional and other rights, and
the qualifications, limitations and restrictions thereof, of such series of shares as follows:

 

1.              
Designation and Amount. The shares of such series shall be designated as “Series F Convertible Preferred
Stock” (the “Series F Preferred Stock”) and the number of shares constituting the Series F Preferred
Stock shall be 1,750,000. Such number of shares may be decreased by resolution of the Board adopted and filed pursuant to the DGCL,
Section 151(g), or any successor provision; provided, that no such decrease shall reduce the number of authorized shares
of Series F Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for
issuance upon the exercise of outstanding options, warrants, convertible or exchangeable securities or other rights to acquire
shares of Series F Preferred Stock. Each share of Series F Preferred Stock shall have a stated value equal to $1.00.

 

2.              
Ranking. With respect to (a) dividends (as provided in Section 3 below), the Series F Preferred Stock shall rank
(i) on parity with the Corporation's (x) common stock, par value $0.01 per share (“Common Stock”), (y) Series
B Convertible Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), and (z) Series G
Convertible Preferred Stock, par value $0.01 per share (the “Series G Preferred Stock”); (ii) senior to
any class or series of preferred stock of the Corporation hereafter created not specifically ranking by its terms senior to or
on a parity with the Series F Preferred Stock; and (iii) junior to any other class or series of preferred stock of the Corporation
hereafter created specifically ranking by its terms senior to the Series F Preferred Stock; and (b) a Liquidation Event (as defined
below), (1) on parity with the Common Stock, (2) senior to any class or series of preferred stock of the Corporation hereafter
created not specifically ranking by its terms senior to or on a parity with the Series F Preferred Stock; and (3) junior to
the Series B Preferred Stock and the Series G Preferred Stock and any other class or series of preferred stock of the Corporation
created concurrently herewith or hereafter created specifically ranking by its terms senior to the Series F Preferred Stock.

 

3.              
Dividends. From and after the date of the issuance of any shares of Series F Preferred Stock (“Original
Issuance Date”), each holder of outstanding shares of Series F Preferred Stock shall be entitled to receive on account
of such shares (participating pari passu with the holders of Common Stock), dividends in cash out of any funds of the Corporation
legally available for the payment thereof, at the same time any dividend will be paid or declared and set apart for payment on
any shares of any Common Stock, in an amount equal to the amount which such holder would have been entitled to receive if such
Series F Preferred Stock were converted to Common Stock under Section 6(a) on the date such dividend is paid or declared and set
apart for payment (assuming for purposes of this Section 3 that all outstanding shares of Series F Preferred Stock are convertible
on such date).

 

 

 

    	 	Schedule 0-1	 

     

    

 

4.              
Voting Rights. Each holder of outstanding shares of Series F Preferred Stock shall be entitled to vote on all matters
submitted to a vote of the holders of the Common Stock. Each share of Series F Preferred Stock shall have one (1) vote, except
as otherwise required by law. Except as provided by law, holders of Series F Preferred Stock shall vote together with the holders
of Common Stock as a single class.

 

5.              
Liquidation Rights. Upon any liquidation, dissolution or winding up of the Corporation (each, a “Liquidation
Event”), whether voluntary or involuntary, each holder of outstanding shares of Series F Preferred Stock shall be entitled
to receive and to be paid out of the assets of the Corporation available for distribution to its stockholders (participating pari
passu with the holders of Common Stock), the amount which such holder would have been entitled to receive if such Series F Preferred
Stock were converted into Common Stock under Section 6 on the date of such liquidation event (the “Liquidation Preference”)
assuming for purposes of this Section 5 that all outstanding shares of Series F Preferred Stock are convertible on such date. From
and after the distribution of such amount, such holder's shares of Series F Preferred Stock shall no longer be deemed to be
outstanding, and all rights of such holder relating to such shares shall cease and terminate.

 

6.              
Conversion.

 

(a)            
Right to Convert. Subject to the terms and conditions of this Section 6, each holder of outstanding shares of Series
F Preferred Stock shall have the right to convert, at any time after __________, 2017, some or all of the outstanding shares of
Series F Preferred Stock then held by such holder into that number of fully-paid and non-assessable shares of Common Stock determined
by dividing (i) 1.95 multiplied by the number of such shares of Series F Preferred Stock to be converted by (ii) the
Conversion Price (as defined below) as of the time of such conversion. Such right of conversion shall be exercised by a holder
of outstanding shares of Series F Preferred Stock by delivery of a written notice to the Corporation stating that the holder elects
to convert a stated number of shares of Series F Preferred Stock into Common Stock and by surrender of a certificate or certificates
for the shares so to be converted (the “Conversion Certificates”) to the Corporation at its principal office
(or such other office or agency of the Corporation as the Corporation may designate by notice in writing to the holders of outstanding
shares of the Series F Preferred Stock) at any time during its usual business hours on the date set forth in such notice.

 

For purposes of this
Section 6(a), the ''Conversion Price” shall be, as of any specified date with respect to any share of Common Stock,
the greater of (A) $1.95 or (B), (i) if the Common Stock is traded on a national securities exchange, the average closing sales
price of the Common Stock reported on the exchange for the 10 trading days immediately preceding the Conversion Date (as defined
below); or (ii) if the Common Stock is not listed on any national securities exchange but is quoted on an inter-dealer quotation
system, the average of the bid and ask prices for the ten trading days immediately preceding the Conversion Date.

 

(b)            
Issuance of Certificate; Time Conversion Effected. Promptly after the receipt of the written notice referred to in
Section 6(a) and the surrender of the Conversion Certificates as provided in Section 6(a), the Corporation shall issue and deliver
to a holder exercising conversion rights under Section 6(a), at such holder's address as it shall appear on the records of the
Corporation, (i) a certificate or certificates representing that number of fully-paid non-assessable shares of Common Stock issuable
upon the conversion of such shares of Series F Preferred Stock pursuant to Section 6(a) and (ii) to the extent that such holder
exercises his, her or its right to convert some but not all of the outstanding shares of Series F Preferred Stock then held by
such holder pursuant to Section 6(a), a certificate or certificates for that number of shares of Series F Preferred Stock represented
by the Conversion Certificates for which such holder is not exercising his, her or its conversion rights under Section 6(a) (if
any). Such conversion shall be deemed to have been effected as of the date on which the written notice delivered pursuant to Section
6(a) is actually received by the Corporation and the Conversion Certificates shall have been duly surrendered (the "Conversion
Date"). All dividends accrued but unpaid with respect to any shares of Series F Preferred Stock converted under Section
6(a) shall he paid in cash within seven (7) days following the date on which such shares are converted (unless there are no legally
available funds with which to make such cash payment, in which event such cash payment shall he made as soon as possible).

 

(c)            
Effect of Subdivision or Combination of Common Stock on Conversions. In case the Corporation shall at any time from
and after the Original Issuance Date subdivide by stock split, stock dividend, or otherwise its outstanding shares of Common Stock
into a greater number of shares, the number of shares of Common Stock into which the Series F Preferred Stock is convertible shall
be proportionately increased; in case the Corporation shall at any time combine (by reverse stock split or otherwise) its outstanding
shares of Common Stock into a lesser number of shares, the number of shares of Common Stock into which the Series F Preferred Stock
is convertible shall be proportionately decreased.

 

 

 

    	 	Schedule 0-2	 

     

    

 

(d)            
Reorganization or Reclassification. If any capital reorganization or reclassification of the capital stock of the
Corporation shall be effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, or assets
with respect to or in exchange for Common Stock, then, as a condition of such reorganization or reclassification, lawful and adequate
provisions shall be made whereby each holder of shares of Series F Preferred Stock shall upon conversion of the Series F Preferred
Stock as described in this Certificate of Designation have the right to receive, upon the basis and upon the terms and conditions
specified herein and in lieu of the shares of Common Stock immediately therefor receivable upon the conversion of such share or
shares of Series F Preferred Stock, such shares of stock, securities, or assets as may be issued or payable with respect to or
in exchange for a number of outstanding shares of Common Stock equal to the number of shares of such Common Stock immediately receivable
upon such conversion had such reorganization or reclassification not taken place. In any such case, appropriate provisions shall
he made with respect to the rights and interests of such holder to the end that the provisions hereof shall thereafter be applicable,
as nearly as may be, in relation to any shares of stock, securities, or assets thereafter deliverable upon the exercise of such
conversion rights.

 

(e)            
Mandatory Conversion; Cancellation. Any shares of Series F Preferred Stock outstanding on ___________ _____, 2021
(the “Mandatory Conversion Date”) shall he automatically converted into that number of fully-paid non-assessable
shares of Common Stock which the holder thereof would have been entitled to receive had such shares of Series F Preferred Stock
been converted into Common Stock pursuant to Section 6(a) on the Mandatory Conversion Date. All certificates evidencing the shares
of Series F Preferred Stock held by a holder shall, on the Mandatory Conversion Date or such earlier date on which such certificates
are so surrendered for conversion, be deemed to have been retired and canceled and the shares of Series F Preferred Stock represented
thereby converted into shares of Common Stock as described above for all purposes. Upon the mandatory conversion of shares of Series
F Preferred Stock pursuant to this Section 6(e), all accrued but unpaid dividends thereon shall be paid in cash within seven (7)
days following the date on which such shares are converted (unless there are no legally available funds with which to make such
cash payment, in which event such cash payment shall be made as soon as possible). The Corporation shall, promptly following the
Mandatory Conversion Date, or such earlier date as the certificates representing all of the shares of Series F Preferred Stock
held by a holder shall have been duly surrendered by such holder pursuant to this Section 6(e), issue and deliver to such holder,
at such holder's address as it shall appear on the records of the Corporation, a certificate or certificates representing that
number of fully-paid non-assessable shares of Common Stock issuable upon conversion of such shares pursuant to this Section 6(e).

 

7.              
Redemption.

 

(a)            
Optional Redemption By Corporation. At any time, from and after ________, 2017, the Corporation has the right to
redeem all or any portion of the then outstanding shares of Series F Preferred Stock (a "Redemption") for a price
per share equal to $1.95 for such share plus any accrued but unpaid dividends on such share (the "Redemption Price").
Any such Redemption will occur not more than sixty (60) days following delivery by the Corporation of a written election notice
containing the information set forth in Section 7(b) below (the "Redemption Election Notice") to the holders of
the shares of Series F Preferred Stock to be redeemed. The Corporation is not required to redeem the shares of the Series F Preferred
Stock proportionately and may redeem shares held by one holder or any number of holders in combination. The allocation among the
holders or shares of Series F Preferred Stock to be redeemed is solely at the discretion of the Corporation. In exchange for the
surrender to the Corporation by the respective holders of Series F Preferred Stock of their certificate or certificates representing
such shares in accordance with Section 7(c) below, the aggregate Redemption Price for all shares held by each holder of shares
of Series F Preferred Stock being redeemed will be payable in cash in immediately available funds to the respective holders of
the Series F Preferred Stock on the applicable Redemption Date.

 

(b)            
Redemption Notice. In a Redemption Election Notice delivered pursuant to Section 7(a), the Corporation shall state:
(a) the number of shares of Series F Preferred Stock held by the holder that the Corporation will redeem on the Redemption Date;
(b) the Redemption Price; (c) the date of the closing of the redemption (the "Redemption Date"); and (d) the manner
and place designated for surrender by the holder to the Corporation of such holder's certificates representing the shares of Series
F Preferred Stock to be redeemed.

 

(c)            
Surrender of Certificates. On or before the Redemption Date, each applicable holder of shares of Series F Preferred
Stock shall surrender the certificate or certificates representing such shares to the Corporation, in the manner and place designated
in the Redemption Election Notice, duly assigned or endorsed for transfer to the Corporation (or accompanied by duly executed stock
powers relating thereto), or, in the event the certificate or certificates are lost, stolen or missing, shall deliver an affidavit
of loss, in the manner and place designated in the Redemption Election Notice. The Corporation shall cancel and retire each surrendered
certificate and shall thereafter make payment of the applicable Redemption Price by certified check or wire transfer to the holder
of record of such certificate.

 

(d)            
Rights Subsequent to Redemption. If, on the applicable Redemption Date, the Redemption Price is paid (or tendered
for payment) for any of the shares to be redeemed on such Redemption Date, then on such date all rights of the holder in the shares
so redeemed and paid or tendered will cease, and such shares will no longer be deemed issued and outstanding.

 

 

 

    	 	Schedule 0-3	 

     

    

 

8.              
Transfer. Other than to other holders of the Series F Preferred Stock, no share of Series F Preferred Stock or any
interest therein may be validly sold, assigned, awarded, pledged, encumbered, disposed or otherwise transferred, for consideration
or otherwise, whether voluntarily, involuntarily or by operation of law (collectively, a “Transfer”), unless
the holder receives from the Corporation its prior written consent to such Transfer. Any attempt to Transfer that requires consent
without such consent by the Corporation shall he null and void in all respects and the purported transferee shall not he recognized
by the Corporation as a holder of Series F Preferred Stock for any purpose whatsoever.

 

9.              
Covenants. So long as any shares of the Series F Preferred Stock are outstanding, the Corporation shall not amend,
alter or repeal any provisions of the Certificate of Incorporation, this Certificate or the Bylaws of the Corporation in a manner
that materially adversely affects the powers, preferences or rights of the Series F Preferred Stock.

 

10.           
Notices. All notices or communications given hereunder shall he in writing and, if to the Corporation, shall be delivered
to it at its principal executive offices and, if to any holder of Series F Preferred Stock, shall be delivered to such holder at
such holder's address as it appears on the stock books of the Corporation.

 

11.           
 Waiver. Any of the rights, powers, preferences and other terms of the Series F Preferred Stock set forth herein
may be waived on behalf of all holders of Series F Preferred Stock by the affirmative written consent of stockholders holding a
majority of the shares of the Series F Preferred Stock.

 

 

 

    	 	Schedule 0-4	 

     

    

 

IN WITNESS WHEREOF,
the Corporation has caused this Certificate of Designation of Series F Preferred Stock of Rennova Health, Inc. to be signed by
its Chief Executive Officer on this ____ day of ________, 2016.

 

	 	
        RENNOVA HEALTH, INC.

	 	 	 
	 	By:	 
	 	 	Name:	  Seamus Lagan
	 	 	Title:	  Chief Executive Officer

 

 

 

 

    	 	Schedule 0-5Exhibit 10.120

 

 

EXECUTIVE TRANSITION AND SEPARATION AGREEMENT
AND GENERAL RELEASE

 

This Executive Transition
and Separation Agreement and General Release ("Agreement") is by and among Rennova Health, Inc. and Medytox Solutions,
Inc. (collectively, the "Company"), and Jason P. Adams ("Executive"), and will become effective upon the 8th
day after execution by the Executive, if not revoked, as set forth in Section 12 below.

 

WHEREAS, the parties
have mutually agreed that Executive's employment by the Company as Chief Financial Officer has been, or will be terminated effective
September 30, 2016 ("Separation Date"); and

 

WHEREAS, the Executive
desires to release all claims and causes of action, if any, Executive may have arising from or relating to Executive's employment
or service or termination from Company or otherwise; and

 

WHEREAS, the Executive
and the Company desire to establish their respective rights and obligations now and for the future;

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which both parties acknowledge, the parties mutually agree
as follows:

 

1.       Separation
of Employment. Executive's employment with Company has, or will terminate effective September 30, 2016, through mutual
agreement of the parties. This Agreement extinguishes all rights, if any, which Executive may have, and obligations, if any, which
Company may have, contractual or otherwise, relating to the employment or termination of employment of Executive with Company,
expressly those termination and severance provisions in Section 4 of the Employment Agreement between Company and Executive, dated
September 9, 2015 (the "Employment Agreement"); provided, that, the post-termination obligations set forth
in Section 4(e), Section 5 (confidentiality/non-disclosure), Section 6 (Intellectual Property Rights), and Section 7 (Restrictive
Covenants), shall remain in full force and effect despite Executive's termination of employment, for the durations expressly stated
therein and as otherwise specified in this Agreement. Executive acknowledges and agrees that the Company has paid all wages and
any other compensation payable for all work performed by Executive, including but not limited to all salary payments, bonuses,
incentive compensation, and reimbursement for business expenses, if any, in connection with Executive’s employment with the
Company.

 

2.       Transition
and Consulting Fees. Commencing on or about October 1, 2016, the Company will transition the duties and responsibilities
relating to the Company's financial affairs from Executive. Executive agrees to assist in facilitating the transition of financial
responsibilities, and to further remain available as a consultant to Company for a period of three (3) months, to ensure a complete
transition of operations, including as to the Company's database and software for which Executive has been engaged to oversee.
Executive shall further be available if required by the Company's financial department or auditors to assist in responding to inquiries
during that period of time. Executive's assistance as a consultant shall be on an "as needed" basis, through and including
December 31, 2016. If Executive remains cooperative and successfully assists in the orderly transition of Executive's responsibilities,
Company will pay Executive a consulting fee in the gross amount of $8,000.00 per month, through December 31, 2016, which payments
shall be paid in three monthly installments commencing after the effective date of this Agreement, but in no event commencing more
than 60 days after Executive's separation from service as an employee. Executive understands and agrees that any additional tax
consequences and/or liability, if any, arising from Executive's receipt of consulting fees under the terms of this Agreement shall
be Executive's sole responsibility, and Executive shall hold Company harmless and indemnify Company as to any such liability, if
any.

 

 

    	 	Page 1 of 5	 

     

    

3.       Full
and Adequate Consideration. Executive acknowledges and agrees that the benefits provided for in this Agreement shall constitute
full and adequate consideration that Executive would not otherwise be entitled but for the promises and obligations set forth in
this Agreement, including Executive's waiver and general release of claims against Company and agreement to cooperate during the
transitional period. Contingent upon Executive's compliance with all of the provisions of this Agreement, Executive shall receive
the following benefits as consideration:

 

(a)       Stock
Options. Upon the effectiveness of this Agreement, the Company shall issue to Executive a total of 83,333 shares of common
stock, par value $.01 per share (the "Common Stock"), pursuant to a grant under the 2007 Incentive Award Plan, which
shall be evidenced by a separate grant agreement in substantially the form attached (the "Grant Agreement"). The shares
of Common Stock shall be valued at $.30 per share.

 

(b)       Continuation
of Health Insurance Benefits. If the Executive currently maintains health insurance benefits through the Company's health
insurance carrier, Company shall continue to maintain this coverage (as is) through November 30, 2016, including payment of
100% of the premiums for family dependent coverage Executive may thereafter elect, at Executive's option and own expense, to continue
health insurance benefits through COBRA, to the extent Executive is eligible under the terms of the federal or state “COBRA”
law, as may be applicable.

 

4.       Covenant
Not to Sue. By entering into this Agreement, Executive does not waive Executive's right to file a complaint or charge with
the Equal Employment Opportunity Commission or any other local, state, or federal administrative body or government agency that
is authorized to enforce or administer any law, rule, or regulation. Further, nothing in this Agreement shall be construed to prohibit
Executive from: (i) reporting possible violations of any law, rule or regulation to any governmental agency or entity charged with
enforcement of any law, rule or regulation, or (ii) making other disclosures that are protected under the whistleblower provisions
of any law, rule or regulation. Notwithstanding the foregoing, Executive expressly waives Executive’s right to recover
damages and to be awarded equitable and/or injunctive relief against the Company or each or any of the Released Parties (defined
in Section 5) in connection with any administrative or court action, and whether brought by Executive or on Executive’s behalf,
related in any way to the matters released herein. However, Executive does not waive any right Executive may have to recover
a bounty or reward from the Securities and Exchange Commission in connection with the disclosure of information to the Commission.

 

5.       Full
and General Release. Executive knowingly and voluntarily agrees to waive, settle, release and discharge the Company and
all of its present or former subsidiaries and affiliates, parent or related entities, including but not limited to Rennova Health,
Inc., Medytox Solutions, Inc., and all of their respective affiliates, predecessors, successors, limited partners, general partners,
operating divisions, joint ventures and all related entities thereof, as well as their respective directors, officers, Executives,
agents, attorneys, shareholders, managers, members and executive benefit plans and their fiduciaries and administrators (collectively
the "Released Parties"), from any and all claims, demands, damages (compensatory or punitive), actions or causes of action,
whether in tort or contract, at law or in equity, for intentional conduct, negligence, or in strict liability, including any claims
for wages, salary, conditions, benefits, incentives, expenses, costs, attorneys fees, damages, compensation or remuneration which
Executive has against any of them arising out of or relating to Executive's employment with the Company or the termination or any
other change of status of Executive's employment with the Company, or otherwise, including but not limited to claims under the
following statutes: the Age Discrimination in Employment Act ("ADEA"); the Older Workers Benefit Protection Act ("OWBPA");
Title VII of the Civil Rights Act of 1964, as amended 1991, 42 U.S.C. § 1981; the Americans with Disabilities Act ("ADA");
the Executive Retirement Income Security Act ("ERISA"); the Consolidated Omnibus Budget Reconciliation Act ("COBRA");
the Occupational Safety and Health Act ("OSHA"); the Fair Labor Standards Act ("FLSA"); the Family and Medical
Leave Act ("FMLA"); the Equal Pay Act ("EPA"); the Worker Adjustment and Retraining Notification Act ("WARN");
the Immigration Reform and Control Act ("IRCA"); the Sarbanes-Oxley Act; the Federal False Claims Act; the Internal Revenue
Code; the National Labor Relations Act; and any and all other local, state and/or federal human or civil rights, wage-hour, pension
or labor laws, rules, regulations and/or ordinances which relate to employment, discrimination, retaliation, or payment of wages
or other compensation or otherwise.

 

 

    	 	Page 2 of 5	 

     

    

6.       Binding
Release. This Agreement is binding on the parties hereto and their respective successors, heirs, administrators, executors
and assigns. The rights and benefits of Executive under this Agreement being personal to the Executive, they may not be assigned
by Executive without the prior written consent of Company. However, Executive expressly acknowledges and agrees that the provisions
of this Agreement, and any and all terms which are expressly incorporated herein, are enforceable against Executive by the Company's
successors and/or assigns, expressly including the post-termination obligations set forth in Section 4(e), Section 5 (confidentiality/non-disclosure),
Section 6 (Intellectual Property Rights), and Section 7 (Restrictive Covenants) of the Employment Agreement.

 

7.       Non-Admission
of Liability.  By entering into this Agreement, neither Executive nor any Released Party admits any liability or wrongdoing.

 

8.       Non-Interference
with Executive's Agency Rights. Executive understands that the terms of this Agreement, including the provisions regarding
waiver and release, cooperation, and any and all confidentiality/non-disclosure covenants expressly incorporated herein, are not
intended to interfere with or waive any right (if any such right otherwise existed) to file a charge, cooperate, testify or participate
in an investigation with any appropriate federal or state governmental agency, including the ability to communicate with such agency.
Executive understands that nothing contained in this Agreement limits Executive's ability to file a charge or complaint with the
EEOC, the NLRB, OSHA, the SEC or any other federal, state, or local government agency or commission ("Government Agencies").
Executive further understands that this Agreement does not limit Executive's ability to communicate with any Government Agencies
or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing
documents or other information, without notice to the Company. This Agreement does not limit Executive's right to receive an award
for information provided to any Government Agencies.

 

9.       Entire
Understanding. This Agreement and the Grant Agreement constitute the sole and entire agreement of the parties with respect
to the subject matter hereof, and supersede any prior or contemporaneous understandings or agreements between the parties, whether
oral or written, on such subject matter, except as expressly provided herein; provided, that, the provisions of the
Employment Agreement, expressly including the post-termination obligations set forth in Section 4(e), Section 5 (confidentiality/non-disclosure),
Section 6 (Intellectual Property Rights), and Section 7 (Restrictive Covenants), shall remain in full force and effect despite
Executive's termination of employment, for the durations expressly stated therein and as otherwise specified in this Agreement.

 

10.       Agreement
Voluntary. Executive acknowledges and agrees that Executive has carefully read this Agreement and understands that, except
as expressly reserved herein, it is a release of all claims, known and unknown, past or present. Executive warrants that Executive
is fully competent to execute this Agreement which Executive understands to be contractual. Executive further acknowledges that
Executive executes this Agreement of Executive's own free will, after having a reasonable period of time to review, study and deliberate
regarding its meaning and effect, and after being advised in writing to consult an attorney, and without reliance on any representation
of any kind or character not expressly set forth herein. Further, Executive executes this Agreement fully knowing its effect and
voluntarily for the consideration described herein.

 

 

    	 	Page 3 of 5	 

     

    

11.       Miscellaneous
Provisions. This Agreement shall be governed by the laws of the State of Florida, without regard to conflict of law principles,
and any action or dispute between the parties to enforce the terms of this Agreement shall be heard by a JUDGE, NOT A JURY, and
the prevailing party shall be entitled to reasonable attorneys fees and costs in connection with such action or dispute. The Parties
agree that the venue for any claims or disputes concerning, relating to, or arising out of this Agreement shall be in state court
in Palm Beach County Florida. This Agreement shall not be modified unless beforehand in writing, signed by all parties. Any waiver
of any part of this Agreement shall not be a waiver of any other part of the whole, nor shall any waiver of a breach of this Agreement
in whole or in part constitute a waiver of any other or succeeding breach. In case any one or more of the provisions in this Agreement,
or a portion thereof, shall be held to be invalid, illegal or unenforceable for any reason, the invalidity, illegality or unenforceability
of any provisions or portions shall not affect any other provision or portion hereof; this Agreement shall be construed as if the
invalid, illegal or unenforceable provision or portion had never been contained in this Agreement. A court is authorized to modify
this Agreement, but only to the extent necessary to make the Agreement enforceable.

 

12.       Effective
Date.  Executive acknowledges and agrees that Executive: (i) is receiving, pursuant to this Agreement, consideration in
addition to anything of value to which Executive is already entitled (ii) does not, by the terms of this Agreement, waive claims
or rights that may arise after the date Executive executes this Agreement; (iii) has the right to review this Agreement for up
to twenty-one (21) days; (iv) has been advised in writing to consult with counsel of Executive's own choosing regarding the terms
of this Agreement prior to executing this Agreement, and has so availed of the opportunity for consultation with counsel to the
full extent Executive desires; (v) if Executive executes this Agreement, has seven (7) days following the execution of this Agreement
to revoke this Agreement (any such revocation will not be effective unless it is in writing and is received by and no later than
the close of business on the seventh day after execution) and (vi) this Agreement shall not become effective or enforceable until
the revocation period has expired. Executive acknowledges and agrees that any modifications, material or otherwise, made to this
Agreement after it is initially provided to Executive do not restart the running of the consideration period.

 

[Signature Page Follows]

 

 

 

 

    	 	Page 4 of 5	 

     

    

 

IN WITNESS WHEREOF,
the parties freely and voluntarily execute this Agreement as follows:

 

	RENNOVA HEALTH, INC.	 
	 	 
	By: /s/ Seamus Lagan	 
	Print Name: Seamus Lagan	 
	Title: CEO	 
	Date of signature: 9/28/16	 
	 	 
	MEDYTOX SOLUTIONS, INC.	JASON P. ADAMS
	 	 
	By: /s/ Seamus Lagan	/s/ Jason P. Adams
	Print Name: Seamus Lagan	Print Name:  Jason P. Adams
	Title: CEO	Date of signature: 9/28/16
	Date of signature: 9/28/16	 

 

 

 

 

 

    	 	Page 5 of 5	 

     

    

 

RENNOVA HEALTH, INC.

 

2007 INCENTIVE AWARD PLAN

 

 GRANT AGREEMENT

 

 

 

THIS GRANT AGREEMENT (this “Agreement”), is made and effective as of this  ____ day of _________, 2016 (the
“Grant Date”), by and between Rennova Health, Inc., a Delaware corporation (“Rennova”), and _________________ (the “Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Rennova
is desirous of increasing the incentive of the Participant whose contributions are important to the continued success of Rennova;

 

NOW, THEREFORE,
in consideration of the foregoing, and for other good and valuable consideration, Rennova hereby grants the Participant an award
pursuant to the Rennova Health, Inc. 2007 Incentive Award Plan (the “Plan”) subject to the terms and conditions below.
Capitalized terms not defined herein shall have the meaning ascribed thereto in the Plan.

 

1.            GRANT
OF RESTRICTED STOCK

 

Pursuant
to the provisions of the Plan, the Committee hereby awards to the Participant _______  shares of common stock
subject to the terms and conditions of the Plan and the terms and conditions set forth herein. 

 

2.            VESTING

 

Subject to Section
4 hereof, the common stock shall become vested upon the Grant Date (the "Vesting Date").
There shall be no proportionate or partial vesting in the period between Grant Date and the Vesting Date.

 

3.            TRANSFER
AND SHAREHOLDER RIGHTS

 

(a)       Transfer. Participant
shall not sell, negotiate, transfer, pledge, hypothecate, assign or otherwise dispose of the common stock until the
applicable restricted period has lapsed.

 

(b)       Shareholder
Rights. Until the expiration of the applicable restricted period, (i) the common stock shall be treated as
outstanding, (ii) unless otherwise provided in the Plan or herein, the Participant holding shares of common stock
may exercise full rights with respect to such shares, and (iii) the Participant holding shares of common stock shall
be entitled to receive all dividends and other distributions paid with respect to such shares while they are so held. In the
discretion of the Committee, dividends or other distributions with respect to common stock may be (a) be subject to the
same restrictions on transferability and forfeitability as the shares of common stock with respect to which they were
paid, and (b) placed in escrow until the expiration of applicable restrictions.

 

 

    	 	1 	 

     

    

 

4.            TERMINATION
OF EMPLOYMENT

 

Upon the Participant’s
termination of employment and other service with the Company for any reason, the unvested portion of the common stock as of
the time of such termination shall be immediately forfeited to Rennova and the Participant shall have no rights whatsoever with
respect to such forfeited common stock.

 

5.            MISCELLANEOUS

 

(a)       Controlling
Law. This Agreement and all questions relating to its validity, interpretation, performance, and enforcement (including, without
limitation, provisions concerning limitations of actions), shall be governed by, and construed in accordance with the laws of the
State of Delaware, without application to the principles of conflict of laws.

 

(b)       Provisions
of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan, including, without limitation,
the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by
the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. If and to the extent that
this Agreement conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and
this Agreement shall be deemed to be modified accordingly.

 

(c)       Withholding.
In connection with  the common stock, the Participant agrees (a) to pay to the Company, or make arrangements satisfactory
to the Company regarding payment of, any federal, state or local, domestic or foreign taxes of any kind required by law to
be withheld in connection with the common stock and (b) that the Company shall, to the extent permitted by law, have the
right to deduct from any payment of any kind otherwise due to the Participant any federal, state or local taxes of any kind
required by law to be withheld with respect to the Participant.

 

(d)       No
Third-Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person other than the parties and
their respective successors and permitted assigns.

 

(e)       Entire
Agreement; Amendments. This Agreement constitutes the entire agreement among the parties and supersedes any prior understandings,
agreements, or representations by or among the parties, written or oral, that may have related in any way to the subject matter
hereof. Unless otherwise provided in the Plan or herein, this Agreement may not be amended, supplemented, or modified in whole
or in part except by an instrument in writing signed by the party or parties against whom enforcement of any such amendment, supplement,
or modification is sought.

 

(f)       No
Rights to Continued Employment. Not Compensation for Certain Purposes. Nothing contained herein shall give the Participant
the right to be retained in the employment or service of the Company or any of its subsidiaries or affiliates or affect the right
of any such employer to terminate the Participant. Any payment or benefit paid to the Participant with respect to this award shall
not be considered to be part of the Participant’s salary or compensation and thus, shall not be taken into account for purposes
of determining the Participant’s termination indemnity, severance pay, retirement or pension payment, or any other employee
benefits, except to the extent required under applicable law.

 

(g)       Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original and all of which together
will constitute one and the same instrument.

 

[SIGNATURES ON FOLLOWING
PAGE]

 

 

    	 	2 	 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement as of the day and year first above written.

 

 

 

	 	RENNOVA HEALTH, INC.:
	 	 
	 	By:______________________________
	 	Name:____________________________
	 	Title:_____________________________
	 	 
	 	 
	 	PARTICIPANT:
	 	 
	 	Name:____________________________
	 	Address:__________________________
	 	              __________________________

 

 

 

 

 

 

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]